$MOBO MOBILE LADS CORP., Announces a Change of Business Direction to Psychedelics
Press Release | 02/24/2022
TORONTO, ON / ACCESSWIRE / February 24, 2022 / MOBILE LADS, CORP. (OTC PINK:MOBO) is pleased to announce a change of Business Direction into the Pharmaceutical Life Sciences sector.

MOBILE LADS will be focusing its efforts on research and development of Psychedelics, with an aim to address the global problem of various chronic neurological disorders, mental illness, and related ailments.

Psychedelic Medicines are an emerging therapeutic paradigm gaining increased international acceptance. MOBILE LADS has been evaluating several promising ventures with research fellows and manufacturing laboratories and expects to conclude a serious of business partnerships shortly.

MOBILE LADS' mandate is to develop psychedelic medicine research and treatments, and will be changing its name to "Avail Scientific" shortly.

Contact:
Mobile Lads, Corp.
Press Relations
michael@mobilelads.com
Phone: 1.800.470.9216

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking

$NUKK Nukkleus, Inc., a market leader in modern global payments and multi-asset trading technology, to combine with Brilliant Acquisition Corp.
Press Release | 02/23/2022
Nukkleus, Inc., a market leader in modern global payments and multi-asset trading technology, to combine with Brilliant Acquisition Corp.
- Transaction Values Nukkleus at pre-Transaction Valuation of $140 million
- Expected to be Listed on Nasdaq Capital Market Under the Ticker Symbol "NUKK" following Expected Transaction Close in Second or Third Quarter of 2022
PR Newswire

NEW YORK, Feb. 23, 2022

NEW YORK, Feb. 23, 2022 /PRNewswire/ -- Nukkleus, Inc. (f/k/a Compliance & Risk Management Solutions Inc.) (OTC: NUKK) ("Nukkleus" or the "Company"), today announced the signing of a merger agreement for a proposed business combination with Brilliant Acquisition Corp (Nasdaq: BRLI) ("Brilliant"), a publicly-traded special purpose acquisition company formed in the British Virgin Islands. The transaction values the Company at an enterprise value of approximately $140 million.

Management Comments

"Nukkleus is extremely pleased to move toward our planned merger with Brilliant. We are very excited that Brilliant has recognized the opportunity Nukkleus provides its shareholders. Nukkleus, through the use of leading edge technology, bridges many asset class execution points and applies this technology to revolutionize global money movement." - Emil Assentato, Nukkleus's CEO & Chairman

Nukkleus Strategy Pillars

Technology: multi-asset trading technology.
Trading: Crypto exchange-traded products and fiat-to-crypto exchange services.
Payments: Crypto enabled multi-currency cross-border payments.
Data: Financial market data, AI analytics and research for FX, CFDs and crypto.
Transaction Overview

Under the terms of the merger agreement with Brilliant, a newly formed British Virgin Islands company and a wholly-owned subsidiary of Nukkleus will merge with and into Brilliant, with Brilliant surviving the Merger as a wholly owned subsidiary of Nukkleus. Nukkleus, as the parent company of Brilliant, will issue common stock to the shareholders of Brilliant. The merger agreement contemplates that, prior to the closing of the proposed transaction, Nukkleus will undertake a reverse stock split at a ratio of 1:25.146, or such other ratio as may be agreed between Nukkleus and Brilliant.

The transaction has been approved by the Boards of Directors of both Nukkleus and Brilliant. The proposed business combination is expected to close in the second or third quarter of 2022, subject to the satisfaction of customary closing conditions, including certain governmental approvals and the approval of the shareholders of each of Nukkleus and Brilliant.

Additional information may be found in the Current Reports on Form 8-K being filed by Nukkleus and Brilliant today with the U.S. Securities and Exchange Commission.

Nukkleus intends to use the proceeds from the transaction to accelerate growth across the Company's network, empowering the Company's portfolio of businesses to pioneer faster and more valuable custody, investment and payments solutions, and building new infrastructures for the digital economy. Nukkleus plans to expand its support of sustainable ESG initiatives, bringing together crypto thought leaders to collaborate on a variety of blockchain-enabled projects, empowering communities and reducing the digital divide.

Upon closing, Nukkleus's common stock is expected to trade on the Nasdaq Capital Market under the ticker symbol "NUKK."

Advisors

ClearThink Capital LLC is acting as financial advisor to Nukkleus. Schiff Hardin LLP is acting as legal advisor to Nukkleus. RedEight Capital Limited, Axiom Capital Management, Inc., and Earlybird Capital Inc. are acting as financial advisors to Brilliant. Loeb & Loeb LLP is acting as legal advisor to Brilliant.

About Nukkleus

Nukkleus, Inc. (OTC: NUKK) combines its world-class multi-asset technology with digital asset exchange execution and payment services, providing institutional clients with a full-service offering to operate effectively in the modern world. Nukkleus's portfolio delivers institutional-grade custody and access to traditional and digital asset markets globally, along with a UK FCA registered EMD agent for the handling of professional and accredited client funds to conduct cryptocurrency conversion to and from fiat currencies.

Nukkleus's common stock trades on the OTC market with the ticker symbol "NUKK."

About Brilliant Acquisition Corp.

Brilliant (Nasdaq: BRLI) is a blank check company organized for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses or entities.

Additional Information and Where to Find It

This press release relates to a proposed business combination transaction between Nukkleus and Brilliant pursuant to which Nukkleus will become the parent company of Brilliant upon the closing of the transactions. In connection with the proposed transaction, Nukkleus intends to file with the Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 (the "proxy statement"). The definitive proxy statement (if and when available) will be delivered to Nukkleus's and Brilliant's shareholders. Each of Nukkleus and Brilliant may also file other relevant documents regarding the proposed transaction with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND SECURITY HOLDERS OF NUKKLEUS AND BRILLIANT ARE URGED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS THAT ARE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION, INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.

Investors and security holders may obtain free copies of the proxy statement (if and when available) and other documents that are filed or will be filed with the SEC by Nukkleus or Brilliant through the website maintained by the SEC at www.sec.gov. Stockholders of Nukkleus will also be able to obtain a copy of the definitive proxy statement, without charge by directing a request to: Nukkleus, Inc., 525 Washington Boulevard, Jersey City, New Jersey 07310. Shareholders of Brilliant will also be able to obtain a copy of the definitive proxy statement, without charge by directing a request to: Brilliant Acquisition Corporation, 99 Dan Ba Road, C-9, Putuo District, Shanghai, Peoples Republic of China.

Participants in the Solicitation

Nukkleus and its directors and executive officers are participants in the solicitation of proxies from the stockholders of Nukkleus in respect of the proposed transaction. Information about Nukkleus's directors and executive officers and their ownership of Nukkleus common stock is set forth in Nukkleus's Annual Report on Form 10-K for the year ended September 30, 2021, filed with the SEC on December 29, 2021. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available. You may obtain free copies of these documents as described in the preceding paragraph.

Brilliant and its directors and executive officers are participants in the solicitation of proxies from the shareholders of Brilliant in respect of the proposed transaction. Information about Brilliant's directors and executive officers and their ownership of Brilliant's ordinary shares is set forth in Brilliant's Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on October 13, 2021. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available. You may obtain free copies of these documents as described above.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, among other things, statements regarding the anticipated benefits of the proposed transaction and the combined company becoming a publicly listed company, the anticipated impact of the proposed transaction on the combined companies' business and future financial and operating results, the anticipated timing of closing of the proposed transaction, the anticipated growth of the space economy, the success and customer acceptance of Nukkleus's product and service offerings, and other aspects of Nukkleus's operations or operating results. Words such as "may," "should," "will," "believe," "expect," "anticipate," "target," "project," and similar phrases that denote future expectations or intent regarding the combined company's financial results, operations, and other matters are intended to identify forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. The outcome of the events described in these forward-looking statements is subject to known and unknown risks, uncertainties, and other factors that may cause future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the ability to complete the proposed transaction within the time frame anticipated or at all; (ii) the failure to realize the anticipated benefits of the proposed transaction or those benefits taking longer than anticipated to be realized; (iii) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of Nukkleus and/or Brilliant securities; (iv) the risk that the transaction may not be completed by Brilliant's business combination deadline and the potential failure to obtain further extensions of the business combination deadline if sought by Brilliant; (v) the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the business combination agreement by the stockholders of Nukkleus, the consummation of the exchange by the Brilliant stockholders, the satisfaction of the minimum cash amount following redemptions by the public shareholders of Brilliant and the receipt of any governmental and regulatory approvals; (vi) the lack of a third party valuation in determining whether or not to pursue the proposed transaction; (vii) the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; (viii) the impact of COVID-19 on Nukkleus's business and/or the ability of the parties to complete the proposed transaction; (ix) the effect of the announcement or pendency of the transaction on Nukkleus's business relationships, performance, and business generally; (x) risks that the proposed transaction disrupts current plans and operations of Nukkleus and potential difficulties in Nukkleus employee retention as a result of the proposed transaction; (xi) the outcome of any legal proceedings that may be instituted against Nukkleus or Brilliant related to the merger agreement or the proposed transaction; (xii) the ability to obtain and maintain the listing of Brilliant's securities and the ability to maintain Nukkleus's securities, in each case on the NASDAQ Stock Market; (xiii) potential volatility in the price of Nukkleus's and/or Brilliant's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Nukkleus operates, variations in performance across competitors, changes in laws and regulations affecting Nukkleus's business and changes in the combined company's capital structure; (xiv) the ability to implement business plans, identify and realize additional opportunities and achieve forecasts and other expectations after the completion of the proposed transaction; (xv) the risk of downturns and the possibility of rapid change in the highly competitive industry in which Nukkleus operates; (xvi) the inability of Nukkleus's and its current and future collaborators to successfully develop and commercialize Nukkleus's services in the expected time frame or at all; (xvii) the risk that the post-combination company may never achieve or sustain profitability; (xviii) Nukkleus's potential need to raise additional capital to execute its business plan, which capital may not be available on acceptable terms or at all; (xix) the risk that the post-combination company experiences difficulties in managing its growth and expanding operations; (xx) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; (xxi) the risk that orders that have been placed by customers for launches with Nukkleus are cancelled or modified; (xxii) that the material weaknesses in Nukkleus's internal control over financial reporting, if not corrected, could adversely affect the reliability of Nukkleus's financial reporting; and (xxiii) the risk of regulatory lawsuits or proceedings relating to Nukkleus's services. The forward-looking statements contained in this press release are also subject to additional risks, uncertainties, and factors, including those described in Nukkleus's and Brilliant's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and other documents filed or to be filed with the SEC by Nukkleus and Brilliant from time to time. The forward-looking statements included in this press release are made only as of the date hereof.

No Offer or Solicitation

This press release is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or to buy any securities or a solicitation of any vote or approval and is not a substitute for the proxy statement/prospectus or any other document that Nukkleus or Brilliant may file with the SEC or send to Nukkleus's or Brilliant's stockholders in connection with the proposed transaction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

Contacts

Nukkleus, Inc.
Melanie Budden
melanie.budden@therealizationgroup.com
+44 (0)7974 937 970

Brilliant Acquisition Corporation
Dr. Peng Jiang
Chief Executive Officer
Brilliant Acquisition Corporation
+ (86) 021-80125497
DC:82355950.6

$NUKK Nukkleus, Inc., a market leader in modern global payments and multi-asset trading technology, to combine with Brilliant Acquisition Corp.
Press Release | 02/23/2022
Nukkleus, Inc., a market leader in modern global payments and multi-asset trading technology, to combine with Brilliant Acquisition Corp.
- Transaction Values Nukkleus at pre-Transaction Valuation of $140 million
- Expected to be Listed on Nasdaq Capital Market Under the Ticker Symbol "NUKK" following Expected Transaction Close in Second or Third Quarter of 2022
PR Newswire

NEW YORK, Feb. 23, 2022

NEW YORK, Feb. 23, 2022 /PRNewswire/ -- Nukkleus, Inc. (f/k/a Compliance & Risk Management Solutions Inc.) (OTC: NUKK) ("Nukkleus" or the "Company"), today announced the signing of a merger agreement for a proposed business combination with Brilliant Acquisition Corp (Nasdaq: BRLI) ("Brilliant"), a publicly-traded special purpose acquisition company formed in the British Virgin Islands. The transaction values the Company at an enterprise value of approximately $140 million.

Management Comments

"Nukkleus is extremely pleased to move toward our planned merger with Brilliant. We are very excited that Brilliant has recognized the opportunity Nukkleus provides its shareholders. Nukkleus, through the use of leading edge technology, bridges many asset class execution points and applies this technology to revolutionize global money movement." - Emil Assentato, Nukkleus's CEO & Chairman

Nukkleus Strategy Pillars

Technology: multi-asset trading technology.
Trading: Crypto exchange-traded products and fiat-to-crypto exchange services.
Payments: Crypto enabled multi-currency cross-border payments.
Data: Financial market data, AI analytics and research for FX, CFDs and crypto.
Transaction Overview

Under the terms of the merger agreement with Brilliant, a newly formed British Virgin Islands company and a wholly-owned subsidiary of Nukkleus will merge with and into Brilliant, with Brilliant surviving the Merger as a wholly owned subsidiary of Nukkleus. Nukkleus, as the parent company of Brilliant, will issue common stock to the shareholders of Brilliant. The merger agreement contemplates that, prior to the closing of the proposed transaction, Nukkleus will undertake a reverse stock split at a ratio of 1:25.146, or such other ratio as may be agreed between Nukkleus and Brilliant.

The transaction has been approved by the Boards of Directors of both Nukkleus and Brilliant. The proposed business combination is expected to close in the second or third quarter of 2022, subject to the satisfaction of customary closing conditions, including certain governmental approvals and the approval of the shareholders of each of Nukkleus and Brilliant.

Additional information may be found in the Current Reports on Form 8-K being filed by Nukkleus and Brilliant today with the U.S. Securities and Exchange Commission.

Nukkleus intends to use the proceeds from the transaction to accelerate growth across the Company's network, empowering the Company's portfolio of businesses to pioneer faster and more valuable custody, investment and payments solutions, and building new infrastructures for the digital economy. Nukkleus plans to expand its support of sustainable ESG initiatives, bringing together crypto thought leaders to collaborate on a variety of blockchain-enabled projects, empowering communities and reducing the digital divide.

Upon closing, Nukkleus's common stock is expected to trade on the Nasdaq Capital Market under the ticker symbol "NUKK."

Advisors

ClearThink Capital LLC is acting as financial advisor to Nukkleus. Schiff Hardin LLP is acting as legal advisor to Nukkleus. RedEight Capital Limited, Axiom Capital Management, Inc., and Earlybird Capital Inc. are acting as financial advisors to Brilliant. Loeb & Loeb LLP is acting as legal advisor to Brilliant.

About Nukkleus

Nukkleus, Inc. (OTC: NUKK) combines its world-class multi-asset technology with digital asset exchange execution and payment services, providing institutional clients with a full-service offering to operate effectively in the modern world. Nukkleus's portfolio delivers institutional-grade custody and access to traditional and digital asset markets globally, along with a UK FCA registered EMD agent for the handling of professional and accredited client funds to conduct cryptocurrency conversion to and from fiat currencies.

Nukkleus's common stock trades on the OTC market with the ticker symbol "NUKK."

About Brilliant Acquisition Corp.

Brilliant (Nasdaq: BRLI) is a blank check company organized for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses or entities.

Additional Information and Where to Find It

This press release relates to a proposed business combination transaction between Nukkleus and Brilliant pursuant to which Nukkleus will become the parent company of Brilliant upon the closing of the transactions. In connection with the proposed transaction, Nukkleus intends to file with the Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 (the "proxy statement"). The definitive proxy statement (if and when available) will be delivered to Nukkleus's and Brilliant's shareholders. Each of Nukkleus and Brilliant may also file other relevant documents regarding the proposed transaction with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND SECURITY HOLDERS OF NUKKLEUS AND BRILLIANT ARE URGED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS THAT ARE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION, INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.

Investors and security holders may obtain free copies of the proxy statement (if and when available) and other documents that are filed or will be filed with the SEC by Nukkleus or Brilliant through the website maintained by the SEC at www.sec.gov. Stockholders of Nukkleus will also be able to obtain a copy of the definitive proxy statement, without charge by directing a request to: Nukkleus, Inc., 525 Washington Boulevard, Jersey City, New Jersey 07310. Shareholders of Brilliant will also be able to obtain a copy of the definitive proxy statement, without charge by directing a request to: Brilliant Acquisition Corporation, 99 Dan Ba Road, C-9, Putuo District, Shanghai, Peoples Republic of China.

Participants in the Solicitation

Nukkleus and its directors and executive officers are participants in the solicitation of proxies from the stockholders of Nukkleus in respect of the proposed transaction. Information about Nukkleus's directors and executive officers and their ownership of Nukkleus common stock is set forth in Nukkleus's Annual Report on Form 10-K for the year ended September 30, 2021, filed with the SEC on December 29, 2021. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available. You may obtain free copies of these documents as described in the preceding paragraph.

Brilliant and its directors and executive officers are participants in the solicitation of proxies from the shareholders of Brilliant in respect of the proposed transaction. Information about Brilliant's directors and executive officers and their ownership of Brilliant's ordinary shares is set forth in Brilliant's Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on October 13, 2021. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available. You may obtain free copies of these documents as described above.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, among other things, statements regarding the anticipated benefits of the proposed transaction and the combined company becoming a publicly listed company, the anticipated impact of the proposed transaction on the combined companies' business and future financial and operating results, the anticipated timing of closing of the proposed transaction, the anticipated growth of the space economy, the success and customer acceptance of Nukkleus's product and service offerings, and other aspects of Nukkleus's operations or operating results. Words such as "may," "should," "will," "believe," "expect," "anticipate," "target," "project," and similar phrases that denote future expectations or intent regarding the combined company's financial results, operations, and other matters are intended to identify forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. The outcome of the events described in these forward-looking statements is subject to known and unknown risks, uncertainties, and other factors that may cause future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the ability to complete the proposed transaction within the time frame anticipated or at all; (ii) the failure to realize the anticipated benefits of the proposed transaction or those benefits taking longer than anticipated to be realized; (iii) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of Nukkleus and/or Brilliant securities; (iv) the risk that the transaction may not be completed by Brilliant's business combination deadline and the potential failure to obtain further extensions of the business combination deadline if sought by Brilliant; (v) the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the business combination agreement by the stockholders of Nukkleus, the consummation of the exchange by the Brilliant stockholders, the satisfaction of the minimum cash amount following redemptions by the public shareholders of Brilliant and the receipt of any governmental and regulatory approvals; (vi) the lack of a third party valuation in determining whether or not to pursue the proposed transaction; (vii) the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; (viii) the impact of COVID-19 on Nukkleus's business and/or the ability of the parties to complete the proposed transaction; (ix) the effect of the announcement or pendency of the transaction on Nukkleus's business relationships, performance, and business generally; (x) risks that the proposed transaction disrupts current plans and operations of Nukkleus and potential difficulties in Nukkleus employee retention as a result of the proposed transaction; (xi) the outcome of any legal proceedings that may be instituted against Nukkleus or Brilliant related to the merger agreement or the proposed transaction; (xii) the ability to obtain and maintain the listing of Brilliant's securities and the ability to maintain Nukkleus's securities, in each case on the NASDAQ Stock Market; (xiii) potential volatility in the price of Nukkleus's and/or Brilliant's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Nukkleus operates, variations in performance across competitors, changes in laws and regulations affecting Nukkleus's business and changes in the combined company's capital structure; (xiv) the ability to implement business plans, identify and realize additional opportunities and achieve forecasts and other expectations after the completion of the proposed transaction; (xv) the risk of downturns and the possibility of rapid change in the highly competitive industry in which Nukkleus operates; (xvi) the inability of Nukkleus's and its current and future collaborators to successfully develop and commercialize Nukkleus's services in the expected time frame or at all; (xvii) the risk that the post-combination company may never achieve or sustain profitability; (xviii) Nukkleus's potential need to raise additional capital to execute its business plan, which capital may not be available on acceptable terms or at all; (xix) the risk that the post-combination company experiences difficulties in managing its growth and expanding operations; (xx) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; (xxi) the risk that orders that have been placed by customers for launches with Nukkleus are cancelled or modified; (xxii) that the material weaknesses in Nukkleus's internal control over financial reporting, if not corrected, could adversely affect the reliability of Nukkleus's financial reporting; and (xxiii) the risk of regulatory lawsuits or proceedings relating to Nukkleus's services. The forward-looking statements contained in this press release are also subject to additional risks, uncertainties, and factors, including those described in Nukkleus's and Brilliant's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and other documents filed or to be filed with the SEC by Nukkleus and Brilliant from time to time. The forward-looking statements included in this press release are made only as of the date hereof.

No Offer or Solicitation

This press release is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or to buy any securities or a solicitation of any vote or approval and is not a substitute for the proxy statement/prospectus or any other document that Nukkleus or Brilliant may file with the SEC or send to Nukkleus's or Brilliant's stockholders in connection with the proposed transaction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

Contacts

Nukkleus, Inc.
Melanie Budden
melanie.budden@therealizationgroup.com
+44 (0)7974 937 970

Brilliant Acquisition Corporation
Dr. Peng Jiang
Chief Executive Officer
Brilliant Acquisition Corporation
+ (86) 021-80125497
DC:82355950.6

$ONPH Oncology Pharma Releases Further Feasibility Studies, Data and Capacities
Press Release | 02/23/2022
SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") looks toward releasing further results of the studies under the Co-Development Agreement with NanoSmart Pharmaceuticals, demonstrating the feasibility and the time release characteristic that is expected to improve the safety and localization profile of the eventual lead candidate formulations.

The active pharmaceutical ingredient, dactinomycin is an actinomycin antibiotic belonging to a class of polypeptide antitumor antibody. It inhibits transcription by binding to DNA at the transcription initiation complex and preventing elongation of RNA chain by RNA polymerase. Dactinomycin has been used both alone and in combination with other drug products to treat a wide range of cancers. Specifically, it has demonstrated clinical benefit for the treatment of pediatric and adult sarcomas and is used routinely as part of standard treatment regimens in clinical practice for the treatment of Ewing's Sarcoma.

Our B-3 Formulation:

Examination of 0.22 um filter post-filtration of B-3 formulation.
No visible residue on filter indicates no large aggregates in formulation.
Likely all particle sizes are < 200 um - deemed suitable for proceeding to physical characterization studies.

Adaptive Design to assess multiple pediatric cancers with superior study statistical powering.
Allows enrichment of promising populations after interim analysis (i.e., mid-study ‘peeks' at the data).
Enables potential for multiple pediatric indications for use.
Can approach FDA with New Drug Application as early as after successful Phase II clinical study.
Exploring simultaneous evaluation for European market (EMA pediatric approvals).
Multidrug Nanoemulsion Potential::

In addition, this proprietary nanoemulsion drug delivery platform has the capacity to incorporate two different drugs within the same nanoemulsion. Each drug is selected to target a different phase in the cell cycle of the tumor cell and thus increase cytotoxicity to the tumor while still having a better safety profile than the predicate free drugs. Oncology Pharma will continue to advance initial development work and nonclinical studies on its lead formulation(s), while exploring additional opportunities utilizing this nanoemulsion platform delivery system. Combination drug formulations have the potential to provide for very significant advantages over existing chemotherapy regimens, making such formulations high valuation opportunities.

Oncology Pharma has licensed and has financed the early feasibility studies to date for this technology from NanoSmart and intends on commercially developing, distributing and utilizing this product and continuing the studies so that it can jointly bring this product to market with the target of initially focusing on the pediatric market. The Company believes the pediatric market is under-served and it gives an edge to Oncology Pharma as a pioneer in this critical market and allows Oncology Pharma to be a significant participant in this well under-served market.

ABOUT ONCOLOGY PHARMA, INC.

ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the 'Company') is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.

ABOUT NANOSMART PHARMACEUTICALS, INC.

NanoSmart® Pharmaceuticals is a privately-held California corporation that is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to enable targeted drug delivery of existing drug therapies to areas of necrosis present in virtually all solid cancer tumors.

FORWARD LOOKING STATEMENTS

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships, and costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.

CONTACTS:

For additional information, please contact the Oncology Pharma at:

One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com

$ONPH Oncology Pharma Releases Further Feasibility Studies, Data and Capacities
Press Release | 02/23/2022
SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") looks toward releasing further results of the studies under the Co-Development Agreement with NanoSmart Pharmaceuticals, demonstrating the feasibility and the time release characteristic that is expected to improve the safety and localization profile of the eventual lead candidate formulations.

The active pharmaceutical ingredient, dactinomycin is an actinomycin antibiotic belonging to a class of polypeptide antitumor antibody. It inhibits transcription by binding to DNA at the transcription initiation complex and preventing elongation of RNA chain by RNA polymerase. Dactinomycin has been used both alone and in combination with other drug products to treat a wide range of cancers. Specifically, it has demonstrated clinical benefit for the treatment of pediatric and adult sarcomas and is used routinely as part of standard treatment regimens in clinical practice for the treatment of Ewing's Sarcoma.

Our B-3 Formulation:

Examination of 0.22 um filter post-filtration of B-3 formulation.
No visible residue on filter indicates no large aggregates in formulation.
Likely all particle sizes are < 200 um - deemed suitable for proceeding to physical characterization studies.

Adaptive Design to assess multiple pediatric cancers with superior study statistical powering.
Allows enrichment of promising populations after interim analysis (i.e., mid-study ‘peeks' at the data).
Enables potential for multiple pediatric indications for use.
Can approach FDA with New Drug Application as early as after successful Phase II clinical study.
Exploring simultaneous evaluation for European market (EMA pediatric approvals).
Multidrug Nanoemulsion Potential::

In addition, this proprietary nanoemulsion drug delivery platform has the capacity to incorporate two different drugs within the same nanoemulsion. Each drug is selected to target a different phase in the cell cycle of the tumor cell and thus increase cytotoxicity to the tumor while still having a better safety profile than the predicate free drugs. Oncology Pharma will continue to advance initial development work and nonclinical studies on its lead formulation(s), while exploring additional opportunities utilizing this nanoemulsion platform delivery system. Combination drug formulations have the potential to provide for very significant advantages over existing chemotherapy regimens, making such formulations high valuation opportunities.

Oncology Pharma has licensed and has financed the early feasibility studies to date for this technology from NanoSmart and intends on commercially developing, distributing and utilizing this product and continuing the studies so that it can jointly bring this product to market with the target of initially focusing on the pediatric market. The Company believes the pediatric market is under-served and it gives an edge to Oncology Pharma as a pioneer in this critical market and allows Oncology Pharma to be a significant participant in this well under-served market.

ABOUT ONCOLOGY PHARMA, INC.

ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the 'Company') is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.

ABOUT NANOSMART PHARMACEUTICALS, INC.

NanoSmart® Pharmaceuticals is a privately-held California corporation that is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to enable targeted drug delivery of existing drug therapies to areas of necrosis present in virtually all solid cancer tumors.

FORWARD LOOKING STATEMENTS

Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships, and costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.

CONTACTS:

For additional information, please contact the Oncology Pharma at:

One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com

$GOGY Golden Grail Tech Pledges Responsible Path to Promote Products Directed at Kids and Tweens
Press Release | 02/23/2022
Golden Grail Tech Pledges Responsible Path to Promote Products Directed at Kids and Tweens
PR Newswire

WESTON, Fla., Feb. 23, 2022

WESTON, Fla., Feb. 23, 2022 /PRNewswire/ -- Golden Grail Technology (OTC: GOGY) a fast-growing company with a strategic mission to innovate, build and streamline the growth of its beverage portfolio through fiscally responsible investing today announced its commitment to responsibly market its recently acquired Tickle Water and future products aimed at kids and tweens, with particular sensitivity to parents. The company issued its pledge as a message to all marketers that brand promotion cannot be at the expense and be detrimental to impressionable youth.

(PRNewsfoto/Golden Grail Technology Corp)

"Today, the power of parents is asserting itself in ways we haven't seen in recent memory, the global pandemic and school shootings are just two quick examples that come to mind, where their positive guidance is more critical than ever. As a result, marketers, brands and the messages they send are coming under more scrutiny by parents looking out for their children and that supports Golden Grail's strategy to re-introduce Tickle Water into the marketplace and underpin the plans we have for extending the brand to additional demographics. As a beverage company Chief Marketing Consultant and mother of a young son, I'm among those that carefully monitor what my child consumes, both nutrition wise and viewing wise and our company pledges to market responsibly and age-appropriately to our youth and asks others to do the same," said Erin Heit, Chief Marketing Consultant, Golden Grail.

The Tickle Water acquisition and planned line extensions aimed to address a tween audience will be guided by responsible marketing that promotes positive attributes emblematic of the brand. Since its inception in 2016, Tickle Water has disrupted the flavored sparkling water segment by offering a healthy and enjoyable sipping option specifically for children based on the proposition that it literally "tickles" their taste buds. Tickle Water is a naturally flavored sparkling water free of preservatives, GMOs, gluten, sodium, sugar, calories and artificial sweeteners. Additionally, all products are certified OU Kosher. The brand aims to alter the beverage landscape for parents and children. Tickle Water was already a proven brand that formerly had a strong retail presence with availability at such national outlets as Walmart, Amazon, Duane Reade/Walgreen's, ShopRite and other popular retailers.

Our kids who have just endured three-years of a deadly pandemic that's impacted their physical and mental health. We have all been surrounded by horrific stories of 'death', sickness and horror," said Heit. "Our youth are always innocent victims and more severely impacted during such disturbing times. Case in point, the CDC reports that ER trips for adolescent suicide attempts soared in 2021 by 22.3 percent. Golden Grail is committing to send a positive message for impressionable kids who already face the overwhelming challenges of teen-hood, a pandemic, increased suicide rates, school shootings, alcohol and drug abuse and so much more to their fragile lives. We challenge other marketers for follow suit."

"We believe all marketers, the beverage industry included, should embrace fun, trendy, creative, eye-catching means by which to gain brand awareness and consumer attention. The message we support is that if you choose to market your brand to our youth, it must be done carefully, thoughtfully and age-appropriately. The company believes that brands that build their hype through showcasing reckless behavior such as portraying tweens getting drunk and behaving exactly counter to what rational and reasonable parents would consider is counterproductive and done just for the sole gain of popularity, aka sales."

"Whether it's a beverage company, a car company, or a tech company, Golden Grail believes that catching the attention of young consumers and gaining brand recognition should be guided by positive messaging and images. Marketing, creativity and boosting sales cannot come at the cost of swaying the young and vulnerable, down a dark path. Doing so is irresponsible, and clearly avoidable."

About Golden Grail Technology

Golden Grail Technology (OTC: GOGY) is a fast-growing company with a strategic mission to innovate, build and streamline the growth of its beverage portfolio through fiscally responsible investing. The company targets brands that have a proven sales history, loyal consumer following, retail presence and strong value proposition who need assistance to get to the next few levels. Golden Grail has been actively acquiring brands within emerging beverage categories, such as energy, flavored water and sparkling flavored water. Our robust product offerings reach multiple demographic and lifestyle categories, creating a dynamic, comprehensive and diverse beverage portfolio.

After an acquisition, the company utilizes a series of operational technologies to apply its business expertise, fiscal techniques and various manufacturing processes know-how to improve the economics and performance of each brand while advancing marketing and distribution for its beverage holdings. The company's focus on fiscal management and development of beverage brands, coupled with its rapidly growing and recognizable portfolio of healthy, functional beverages sets Golden Grail apart as a leader in acquiring and advancing existing beverage brands.

For more information on Golden Grail, visit
www.GoldenGrailBeverages.com

https://twitter.com/golden_grail

Golden Grail's Beverage Portfolio

Tickle Water is a premium sparkling water company dedicated to providing honest and clean hydration. Tickle Water is the first sparkling water in the market created specifically for children, yet enjoyed by all ages, complete with delicious flavors and a recyclable can, making it the perfect beverage for any occasion. Every can of Tickle Water is simply made with premium sparkling water and natural flavors without artificial ingredients, sugar, sodium, or preservatives.

For more information visit http://www.drinkticklewater.com

https://www.facebook.com/drinkticklewater

Trevi Essence Water is a true clean-label beverage with a superior flavor that stays true to the fruit. Trevi has zero sugar, zero calories, no preservatives, no artificial ingredients, gluten free, vegan, kosher and diet friendly. Trevi comes in four delicious flavors Mango Orange, Coconut Lime, Peach and Grapefruit.

For more information visit www.DrinkTrevi.com

https://www.facebook.com/DrinkTrevi

https://www.instagram.com/drinktreviwater/

https://twitter.com/drinktreviwater

Spider Energy Drink is packed with serious energy. This formula is the perfect balance of energy boosting B-vitamins, Taurine, Guarana, Ginseng, Key Levels of Amino Acids and herbal extracts. Made with 100% real sugar, Spider Energy is known as one of the best tasting with a fresh-citrus, smooth and refreshing flavor, without the medicinal aftertaste associated with most energy drinks.

For more information visit https://spiderenergydrink.com/

https://www.facebook.com/SpiderEnergyDrink

https://www.instagram.com/spiderenergydrink/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/golden-grail-tech-pledges-responsible-path-to-promote-products-directed-at-kids-and-tweens-301487973.html

SOURCE Golden Grail Technology Corp

$GOGY Golden Grail Tech Pledges Responsible Path to Promote Products Directed at Kids and Tweens
Press Release | 02/23/2022
Golden Grail Tech Pledges Responsible Path to Promote Products Directed at Kids and Tweens
PR Newswire

WESTON, Fla., Feb. 23, 2022

WESTON, Fla., Feb. 23, 2022 /PRNewswire/ -- Golden Grail Technology (OTC: GOGY) a fast-growing company with a strategic mission to innovate, build and streamline the growth of its beverage portfolio through fiscally responsible investing today announced its commitment to responsibly market its recently acquired Tickle Water and future products aimed at kids and tweens, with particular sensitivity to parents. The company issued its pledge as a message to all marketers that brand promotion cannot be at the expense and be detrimental to impressionable youth.

(PRNewsfoto/Golden Grail Technology Corp)

"Today, the power of parents is asserting itself in ways we haven't seen in recent memory, the global pandemic and school shootings are just two quick examples that come to mind, where their positive guidance is more critical than ever. As a result, marketers, brands and the messages they send are coming under more scrutiny by parents looking out for their children and that supports Golden Grail's strategy to re-introduce Tickle Water into the marketplace and underpin the plans we have for extending the brand to additional demographics. As a beverage company Chief Marketing Consultant and mother of a young son, I'm among those that carefully monitor what my child consumes, both nutrition wise and viewing wise and our company pledges to market responsibly and age-appropriately to our youth and asks others to do the same," said Erin Heit, Chief Marketing Consultant, Golden Grail.

The Tickle Water acquisition and planned line extensions aimed to address a tween audience will be guided by responsible marketing that promotes positive attributes emblematic of the brand. Since its inception in 2016, Tickle Water has disrupted the flavored sparkling water segment by offering a healthy and enjoyable sipping option specifically for children based on the proposition that it literally "tickles" their taste buds. Tickle Water is a naturally flavored sparkling water free of preservatives, GMOs, gluten, sodium, sugar, calories and artificial sweeteners. Additionally, all products are certified OU Kosher. The brand aims to alter the beverage landscape for parents and children. Tickle Water was already a proven brand that formerly had a strong retail presence with availability at such national outlets as Walmart, Amazon, Duane Reade/Walgreen's, ShopRite and other popular retailers.

Our kids who have just endured three-years of a deadly pandemic that's impacted their physical and mental health. We have all been surrounded by horrific stories of 'death', sickness and horror," said Heit. "Our youth are always innocent victims and more severely impacted during such disturbing times. Case in point, the CDC reports that ER trips for adolescent suicide attempts soared in 2021 by 22.3 percent. Golden Grail is committing to send a positive message for impressionable kids who already face the overwhelming challenges of teen-hood, a pandemic, increased suicide rates, school shootings, alcohol and drug abuse and so much more to their fragile lives. We challenge other marketers for follow suit."

"We believe all marketers, the beverage industry included, should embrace fun, trendy, creative, eye-catching means by which to gain brand awareness and consumer attention. The message we support is that if you choose to market your brand to our youth, it must be done carefully, thoughtfully and age-appropriately. The company believes that brands that build their hype through showcasing reckless behavior such as portraying tweens getting drunk and behaving exactly counter to what rational and reasonable parents would consider is counterproductive and done just for the sole gain of popularity, aka sales."

"Whether it's a beverage company, a car company, or a tech company, Golden Grail believes that catching the attention of young consumers and gaining brand recognition should be guided by positive messaging and images. Marketing, creativity and boosting sales cannot come at the cost of swaying the young and vulnerable, down a dark path. Doing so is irresponsible, and clearly avoidable."

About Golden Grail Technology

Golden Grail Technology (OTC: GOGY) is a fast-growing company with a strategic mission to innovate, build and streamline the growth of its beverage portfolio through fiscally responsible investing. The company targets brands that have a proven sales history, loyal consumer following, retail presence and strong value proposition who need assistance to get to the next few levels. Golden Grail has been actively acquiring brands within emerging beverage categories, such as energy, flavored water and sparkling flavored water. Our robust product offerings reach multiple demographic and lifestyle categories, creating a dynamic, comprehensive and diverse beverage portfolio.

After an acquisition, the company utilizes a series of operational technologies to apply its business expertise, fiscal techniques and various manufacturing processes know-how to improve the economics and performance of each brand while advancing marketing and distribution for its beverage holdings. The company's focus on fiscal management and development of beverage brands, coupled with its rapidly growing and recognizable portfolio of healthy, functional beverages sets Golden Grail apart as a leader in acquiring and advancing existing beverage brands.

For more information on Golden Grail, visit
www.GoldenGrailBeverages.com

https://twitter.com/golden_grail

Golden Grail's Beverage Portfolio

Tickle Water is a premium sparkling water company dedicated to providing honest and clean hydration. Tickle Water is the first sparkling water in the market created specifically for children, yet enjoyed by all ages, complete with delicious flavors and a recyclable can, making it the perfect beverage for any occasion. Every can of Tickle Water is simply made with premium sparkling water and natural flavors without artificial ingredients, sugar, sodium, or preservatives.

For more information visit http://www.drinkticklewater.com

https://www.facebook.com/drinkticklewater

Trevi Essence Water is a true clean-label beverage with a superior flavor that stays true to the fruit. Trevi has zero sugar, zero calories, no preservatives, no artificial ingredients, gluten free, vegan, kosher and diet friendly. Trevi comes in four delicious flavors Mango Orange, Coconut Lime, Peach and Grapefruit.

For more information visit www.DrinkTrevi.com

https://www.facebook.com/DrinkTrevi

https://www.instagram.com/drinktreviwater/

https://twitter.com/drinktreviwater

Spider Energy Drink is packed with serious energy. This formula is the perfect balance of energy boosting B-vitamins, Taurine, Guarana, Ginseng, Key Levels of Amino Acids and herbal extracts. Made with 100% real sugar, Spider Energy is known as one of the best tasting with a fresh-citrus, smooth and refreshing flavor, without the medicinal aftertaste associated with most energy drinks.

For more information visit https://spiderenergydrink.com/

https://www.facebook.com/SpiderEnergyDrink

https://www.instagram.com/spiderenergydrink/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/golden-grail-tech-pledges-responsible-path-to-promote-products-directed-at-kids-and-tweens-301487973.html

SOURCE Golden Grail Technology Corp

$CULTF CULT Food Science Completes Seed Investment into Precision Fermentation Dairy Company De Novo Dairy
Press Release | 02/23/2022
CULT Food Science Completes Seed Investment into Precision Fermentation Dairy Company De Novo Dairy
Canada NewsWire

VANCOUVER, BC, Feb. 23, 2022

CULT's Latest Addition to its Cellular Agriculture Portfolio Aims to Commercialize Cell-based Ice Creams, Yogurts and Cheeses While Combatting the Emissions Output from the Traditional Dairy Industry

VANCOUVER, BC, Feb. 23, 2022 /CNW/ - CULT Food Science Corp. ("CULT" or the "Company") (CSE: CULT) (OTC: CULTF) (FRA: LN0), an innovative investment platform with an exclusive focus on cellular agriculture that is advancing the development of novel technologies to provide a sustainable, environmental, and ethical solution to the global factory farming and aquaculture crises, is pleased to announce that it has completed an early-stage investment in De Novo Dairy ("De Novo"). The Company continues to broaden its exposure to a diversified and cell-based product and intellectual property ("IP") pipeline through this net-new exposure to cell-based dairy. CULT joins other notable cellular agriculture ("CellAg") capital allocators like Sustainable Food Ventures in helping accelerate De Novo's commercialization and IP pursuits.

CULT Food Science Corp. (CSE: CULT, OTC: CULTF, FRA: LN0) (CNW Group/CULT Food Science Corp.)

Based in Cape Town, South Africa, De Novo is the first precision fermentation company in Africa that is focused on alternative proteins products such as ice cream, yogurt and cheese. De Novo produces recombinant milk proteins through fermentation, identical to those found in a cow's milk, that can be seamlessly integrated into animal-free dairy products at a commercial scale. As milk proteins are largely associated with the physiochemical behavior, taste and texture of traditional dairy, De Novo's products provide that familiar sensory experience of traditional dairy, as well as the nutritional benefits, but in a far more ethical, sustainable, and efficient manner.

With 57% of all food-related emissions resulting from meat and dairy production1, De Novo aims to advance a sustainable and creative solution to the global greenhouse gas problem. CULT's management team is encouraged by De Novo's progress and looks forward to it bringing a wide range animal-free dairy products to market. The commercialization of De Novo's product pipeline is expected to enable consumers to enjoy the real taste, texture and nutritional value of animal-derived dairy, but without the factory farming, lactose, hormones or antibiotics.2

Management Commentary

"It really is inspiring to see all the international support De Novo Dairy has been receiving for our mission to improve human nutrition whilst removing animals from the food chain. Having CULT Food Science on our side has definitely taken it to the next level, and we look forward to what we will be achieving together in the coming years," added Jean Louwrens, CEO of De Novo.

"CULT is excited to add De Novo to its growing portfolio of innovators that are working to change the global food industry for the better. We are keenly interested in De Novo's work and how it might revolutionize the dairy business and alter consumer demand for traditional dairy products," said Lejjy Gafour, President of CULT. "Finding ways to convert longstanding industries that are harmful to animals and the environment into a sustainable alternative is the wave of the future and we at CULT are doing what we can to sponsor this shift through our investments," added Mr. Gafour.

Additionally, it has come to the Company's attention that deliberately false and inaccurate information about CULT is being disseminated on-line by or at the direction of parties attempting to discredit the Company. CULT and its legal advisers are currently investigating the matter and intend to take any steps necessary or appropriate to address the situation.

About De Novo Dairy

De Novo Dairy is currently based in Cape Town South Africa, and we are the first precision fermentation company on the African continent within the alternative protein space. We are focused on bringing rich decadent ice cream, nutritious creamy yoghurt and stretchy melty cheese to the market because eating sustainably and ethically shouldn't mean that consumers need to compromise on taste or nutrition.

About CULT Food Science

CULT Food Science Corp. (CSE: CULT) is an innovative investment platform with an exclusive focus on cellular agriculture that is advancing the development of novel technologies to provide a sustainable, environmental, and ethical solution to the global factory farming crisis. The first-of-its-kind in North America, CULT Food Science aims to provide individual investors with unprecedented exposure to the most innovative start-up, private or early-stage cultivated meat, cell-based dairy and other cultured food companies around the world.

Additional information can be found by viewing the Company's website at www.cultfoodscience.com or its regulatory filings on www.sedar.com.

On behalf of the Board of Directors of the Company,

CULT FOOD SCIENCE CORP.

"Lejjy Gafour"
Lejjy Gafour, President

Forward-Looking Information:

Information set forth in this news release may involve forward-looking statements. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address a company's expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include but are not limited to the following risks: those associated with marketing and sale of securities; the need for additional financing; reliance on key personnel; the potential for conflicts of interest among certain officers or directors with certain other projects; and the volatility of common share price and volume. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and except as required by law, the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements. For further information on risk, investors are advised to see the Company's MD&A and other disclosure filings with the regulators which are found at www.sedar.com.

Endnotes

"Meat accounts for nearly 60% of all greenhouse gases from food production, study finds", The Guardian, September 13, 2021, https://www.theguardian.com/environment/2021/sep/13/meat-greenhouses-gases-food-production-study
"What is animal-free dairy protein?", The Perfect Day Incorporated, 2022, https://perfectday.com/faqs/

$CULTF CULT Food Science Completes Seed Investment into Precision Fermentation Dairy Company De Novo Dairy
Press Release | 02/23/2022
CULT Food Science Completes Seed Investment into Precision Fermentation Dairy Company De Novo Dairy
Canada NewsWire

VANCOUVER, BC, Feb. 23, 2022

CULT's Latest Addition to its Cellular Agriculture Portfolio Aims to Commercialize Cell-based Ice Creams, Yogurts and Cheeses While Combatting the Emissions Output from the Traditional Dairy Industry

VANCOUVER, BC, Feb. 23, 2022 /CNW/ - CULT Food Science Corp. ("CULT" or the "Company") (CSE: CULT) (OTC: CULTF) (FRA: LN0), an innovative investment platform with an exclusive focus on cellular agriculture that is advancing the development of novel technologies to provide a sustainable, environmental, and ethical solution to the global factory farming and aquaculture crises, is pleased to announce that it has completed an early-stage investment in De Novo Dairy ("De Novo"). The Company continues to broaden its exposure to a diversified and cell-based product and intellectual property ("IP") pipeline through this net-new exposure to cell-based dairy. CULT joins other notable cellular agriculture ("CellAg") capital allocators like Sustainable Food Ventures in helping accelerate De Novo's commercialization and IP pursuits.

CULT Food Science Corp. (CSE: CULT, OTC: CULTF, FRA: LN0) (CNW Group/CULT Food Science Corp.)

Based in Cape Town, South Africa, De Novo is the first precision fermentation company in Africa that is focused on alternative proteins products such as ice cream, yogurt and cheese. De Novo produces recombinant milk proteins through fermentation, identical to those found in a cow's milk, that can be seamlessly integrated into animal-free dairy products at a commercial scale. As milk proteins are largely associated with the physiochemical behavior, taste and texture of traditional dairy, De Novo's products provide that familiar sensory experience of traditional dairy, as well as the nutritional benefits, but in a far more ethical, sustainable, and efficient manner.

With 57% of all food-related emissions resulting from meat and dairy production1, De Novo aims to advance a sustainable and creative solution to the global greenhouse gas problem. CULT's management team is encouraged by De Novo's progress and looks forward to it bringing a wide range animal-free dairy products to market. The commercialization of De Novo's product pipeline is expected to enable consumers to enjoy the real taste, texture and nutritional value of animal-derived dairy, but without the factory farming, lactose, hormones or antibiotics.2

Management Commentary

"It really is inspiring to see all the international support De Novo Dairy has been receiving for our mission to improve human nutrition whilst removing animals from the food chain. Having CULT Food Science on our side has definitely taken it to the next level, and we look forward to what we will be achieving together in the coming years," added Jean Louwrens, CEO of De Novo.

"CULT is excited to add De Novo to its growing portfolio of innovators that are working to change the global food industry for the better. We are keenly interested in De Novo's work and how it might revolutionize the dairy business and alter consumer demand for traditional dairy products," said Lejjy Gafour, President of CULT. "Finding ways to convert longstanding industries that are harmful to animals and the environment into a sustainable alternative is the wave of the future and we at CULT are doing what we can to sponsor this shift through our investments," added Mr. Gafour.

Additionally, it has come to the Company's attention that deliberately false and inaccurate information about CULT is being disseminated on-line by or at the direction of parties attempting to discredit the Company. CULT and its legal advisers are currently investigating the matter and intend to take any steps necessary or appropriate to address the situation.

About De Novo Dairy

De Novo Dairy is currently based in Cape Town South Africa, and we are the first precision fermentation company on the African continent within the alternative protein space. We are focused on bringing rich decadent ice cream, nutritious creamy yoghurt and stretchy melty cheese to the market because eating sustainably and ethically shouldn't mean that consumers need to compromise on taste or nutrition.

About CULT Food Science

CULT Food Science Corp. (CSE: CULT) is an innovative investment platform with an exclusive focus on cellular agriculture that is advancing the development of novel technologies to provide a sustainable, environmental, and ethical solution to the global factory farming crisis. The first-of-its-kind in North America, CULT Food Science aims to provide individual investors with unprecedented exposure to the most innovative start-up, private or early-stage cultivated meat, cell-based dairy and other cultured food companies around the world.

Additional information can be found by viewing the Company's website at www.cultfoodscience.com or its regulatory filings on www.sedar.com.

On behalf of the Board of Directors of the Company,

CULT FOOD SCIENCE CORP.

"Lejjy Gafour"
Lejjy Gafour, President

Forward-Looking Information:

Information set forth in this news release may involve forward-looking statements. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address a company's expected future business and financial performance, and often contain words such as "anticipate", "believe", "plan", "estimate", "expect", and "intend", statements that an action or event "may", "might", "could", "should", or "will" be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include but are not limited to the following risks: those associated with marketing and sale of securities; the need for additional financing; reliance on key personnel; the potential for conflicts of interest among certain officers or directors with certain other projects; and the volatility of common share price and volume. Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and except as required by law, the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements. For further information on risk, investors are advised to see the Company's MD&A and other disclosure filings with the regulators which are found at www.sedar.com.

Endnotes

"Meat accounts for nearly 60% of all greenhouse gases from food production, study finds", The Guardian, September 13, 2021, https://www.theguardian.com/environment/2021/sep/13/meat-greenhouses-gases-food-production-study
"What is animal-free dairy protein?", The Perfect Day Incorporated, 2022, https://perfectday.com/faqs/

$CLABF Vancouver discovery will make ‘Magic Mushroom’ mental health care cheaper
Press Release | 02/23/2022
Vancouver, BC, Feb. 23, 2022 (GLOBE NEWSWIRE) -- A team of Vancouver scientists has discovered a new process to cost-effectively make psilocybin, the active ingredient in magic mushrooms, paving the way for greater and more affordable treatments for a range of addictions and mental health conditions.

Recent research has found psilocybin is effective in the treatment of alcohol and opiate addiction, PTSD, depression, and anxiety. Research into other potential applications is ongoing. According to scientists at John Hopkins University the current cost of $7,000 - $10,000 per gram of psilocybin, makes it a prohibitively expensive ingredient in medical regimens and academic research.

A team out of Vancouver’s Core One Labs led by Dr. Robert Hancock, a globally renowned University of British Columbia (UBC) microbiologist and Canada Research Chair Holder in Health and Genomics, has created a new process they expect will bring that cost under $100 a gram by the end of 2022.

“It’s a game changer that allows for rapid, stable and cost-effective psilocybin production to bring the price down of the psychedelic compound that is showing enormous promise in treating addiction, depression and PTSD,” said Dr. Hancock, an Order of Canada recipient.

Psilocybin, Dr Hancock said, has been trialled, tested, legalised and decriminalised in many parts of the world and its “exceptional properties” could transform the mental-health care field.

The new process the team developed uses specially constructed, optimised DNA sequences making bacteria into biological factories for psilocybin production via a fermentation process, allowing the substance to be created in a lab under controlled conditions.

The breakthrough discovery comes in the wake of Health Canada approving the Special Access Program (SAP) use of psilocybin in psychedelic assisted therapy for mental illness, which afflicts 1 in 5 people in Canada every year.

A study from the Institute of Psychiatry, Psychology, & Neuroscience (IoPPN) at King’s College London, found that psilocybin can be safely administered with no detrimental effects in healthy people.

In the Pacific Northwest, Oregon has legalised psilocybin treatment for mental health issues while a pair of Washington State lawmakers earlier this month introduced legislation that would legalize “supported psilocybin experiences” by adults 21 and older.

“Nationally and internationally recognized medical institutions have shown that Psilocybin can help treat a variety of behavioral health conditions,” stated the Washington bill, “including but not limited to addiction, depression, anxiety disorders, and end-of-life psychological distress.”

“Psychotherapists around the world are reporting psilocybin treatment, is showing some of the best results compared to any therapy in addressing addiction, anxiety, depression and PTSD, said Joel Shacker, Chief Executive Officer of Core One Labs Inc., which has filed for a patent on its new discovery.

“The science and engineering by our scientists is playing a significant role in furthering mental health research with cost-effective psychedelic compounds,” he said.

The company’s scientists are now working with Dr. Hancock and global partners for the advancement of psychedelic-derived treatments for mental health disorders including neurodegenerative diseases, like Parkinson’s and Alzheimer’s.

McMillan LLP research recently reported that psychedelics have come a long way since the 1970s, at which time they faced a negative backlash as a result of the “war on drugs” in the United States, and corresponding restrictions in countries such as Canada.

“With a growing body of research, shifting demographics and a general openness to evaluate non-conventional ways to deal with existing challenges, the public has become more receptive to psychedelics for medical and therapeutic purposes,” said the business law firm.

The Canadian Psychedelic Association has also revealed survey findings from Nanos Research which demonstrated that 82% of Canadians approve the use of psilocybin-assisted therapy, and 78% would support a government that legalized the same.



Shawn Hall
(604) 619-7913
shawn@apogeepr.ca

$CLABF Vancouver discovery will make ‘Magic Mushroom’ mental health care cheaper
Press Release | 02/23/2022
Vancouver, BC, Feb. 23, 2022 (GLOBE NEWSWIRE) -- A team of Vancouver scientists has discovered a new process to cost-effectively make psilocybin, the active ingredient in magic mushrooms, paving the way for greater and more affordable treatments for a range of addictions and mental health conditions.

Recent research has found psilocybin is effective in the treatment of alcohol and opiate addiction, PTSD, depression, and anxiety. Research into other potential applications is ongoing. According to scientists at John Hopkins University the current cost of $7,000 - $10,000 per gram of psilocybin, makes it a prohibitively expensive ingredient in medical regimens and academic research.

A team out of Vancouver’s Core One Labs led by Dr. Robert Hancock, a globally renowned University of British Columbia (UBC) microbiologist and Canada Research Chair Holder in Health and Genomics, has created a new process they expect will bring that cost under $100 a gram by the end of 2022.

“It’s a game changer that allows for rapid, stable and cost-effective psilocybin production to bring the price down of the psychedelic compound that is showing enormous promise in treating addiction, depression and PTSD,” said Dr. Hancock, an Order of Canada recipient.

Psilocybin, Dr Hancock said, has been trialled, tested, legalised and decriminalised in many parts of the world and its “exceptional properties” could transform the mental-health care field.

The new process the team developed uses specially constructed, optimised DNA sequences making bacteria into biological factories for psilocybin production via a fermentation process, allowing the substance to be created in a lab under controlled conditions.

The breakthrough discovery comes in the wake of Health Canada approving the Special Access Program (SAP) use of psilocybin in psychedelic assisted therapy for mental illness, which afflicts 1 in 5 people in Canada every year.

A study from the Institute of Psychiatry, Psychology, & Neuroscience (IoPPN) at King’s College London, found that psilocybin can be safely administered with no detrimental effects in healthy people.

In the Pacific Northwest, Oregon has legalised psilocybin treatment for mental health issues while a pair of Washington State lawmakers earlier this month introduced legislation that would legalize “supported psilocybin experiences” by adults 21 and older.

“Nationally and internationally recognized medical institutions have shown that Psilocybin can help treat a variety of behavioral health conditions,” stated the Washington bill, “including but not limited to addiction, depression, anxiety disorders, and end-of-life psychological distress.”

“Psychotherapists around the world are reporting psilocybin treatment, is showing some of the best results compared to any therapy in addressing addiction, anxiety, depression and PTSD, said Joel Shacker, Chief Executive Officer of Core One Labs Inc., which has filed for a patent on its new discovery.

“The science and engineering by our scientists is playing a significant role in furthering mental health research with cost-effective psychedelic compounds,” he said.

The company’s scientists are now working with Dr. Hancock and global partners for the advancement of psychedelic-derived treatments for mental health disorders including neurodegenerative diseases, like Parkinson’s and Alzheimer’s.

McMillan LLP research recently reported that psychedelics have come a long way since the 1970s, at which time they faced a negative backlash as a result of the “war on drugs” in the United States, and corresponding restrictions in countries such as Canada.

“With a growing body of research, shifting demographics and a general openness to evaluate non-conventional ways to deal with existing challenges, the public has become more receptive to psychedelics for medical and therapeutic purposes,” said the business law firm.

The Canadian Psychedelic Association has also revealed survey findings from Nanos Research which demonstrated that 82% of Canadians approve the use of psilocybin-assisted therapy, and 78% would support a government that legalized the same.



Shawn Hall
(604) 619-7913
shawn@apogeepr.ca

$AWSL Atlantic Power and Infrastructure’s KB Industries Flexi(R)-Pave provides a Welcome Solution for Pump Tracks
Press Release | 02/23/2022
Atlantic's KB Industries proprietary Flexi®-Pave installation at "Velosolutions Pump Track" installed at Big Rock Quarry in North Little Rock, Arkansas gives wheeled sports fans an ideal facility

TAMPA BAY, FL / ACCESSWIRE / February 23, 2022 / Atlantic Power & Infrastructure Corp. (OTC PINK:AWSL) is pleased to announce it has completed the installation of the recently opened ‘PUMP TRACK' at the popular Big Rock Quarry Bike Park in Little Rock, Arkansas

Flexi®-Pave was chosen to replace the traditional grass or turf, as Flexi®-Pave strong and porous finish provides the necessary drainage, subsequently increasing the rideable surface areas within the Pump Track. Flexi®-Pave is an ideal alternative for landscaping in this application for many reasons. It allows water drainage, provides low to almost no maintenance for city parks, eliminates the need for weed eating or watering grass. The Flexi®-Pave surface is sturdy enough to allow bikes to ride over without damaging the landscaping and to use in tandem with the actual Pump Track course. Installed by https://velosolutions.com/pump-track-races/ who now view Flexi®-Pave as the surface of choice in future installations due to all its benefits and it's pleasing visual appeal.

About Pump Track

Pump Tracks being a track for wheeled sports equipment that, when ridden properly, does not require pedaling or pushing, but a "pumping" action to maintain momentum. Originally designed for the mountain bike and the BMX scene, now, due to improved construction technology, is also used by skateboarders, and accessible to wheelchairs.

In 2018, Velosolutions in conjunction with Red Bull launched the first global pump track race series, the Red Bull Pump Track World Championships. In 2019 the winning podium included a UCI Gold Medal after joining forces with the Union Cycliste Internationale and became the Red Bull UCI Pump Track World Championships. The future holds the Olympics in its sights and the future sure looks bright.

Learn more at: https://velosolutions.com/pump-track-races/

Big Rock Quarry Park


North Little Rock Parks and Recreation is located at Big Rock Quarry Bike Park, 4000 River Road • North Little Rock, Arkansas. http://nlrpr.org/parks/big_rock_quarry_park

(Installation of Flexi®-Pave not yet shown on their website)

About Flexi®-Pave

Flexi®-Pave uses the natural, vulcanized strength of scrap tires, along with KBI's proprietary technology, and converts the "Recycled Tire Granules" into proven, sustainable infrastructure construction products. This massively porous but strong structural material can be used for a variety of infrastructure applications with demonstrated success. Applications include storm water management, water treatment and shoreline protection projects, including ship docks. Flexi®-Pave offers long and short-term permeability, flexibility, crack resistance (even freeze-thaw conditions) trip hazard resistance and slip resistance. Notable locations include Yellowstone National Park; Arlington National Cemetery; Seaside Park's Band Shell, City of Bridgeport, Connecticut; Red Butte Gardens, Utah; Atlanta Georgia's Iconic Beltline; Kew Botanical Gardens, London England.

About Atlantic Power and Infrastructure Corp.

Atlantic P&I provides environmental technologies including converting recycled tire material into proven, sustainable infrastructure products. Its flagship product Flexi ® -Pave's resounding strength, flexibility and porous nature which protects from land erosion has led to its use in high profile shoreline break walls and other marine and infrastructure projects. The Company's water purification technology removes harmful algae blooms from freshwater rivers and lakes, and Red Tide algae blooms from salt water. The Company further plans to utilize its existing bi-products and relationships to produce waste to energy power generation.

Submit enquires to:

enquiries@apaicorp.com
Visit: www.AtlanticPIC.com
Tel. ++1 (727) 723-3300

Disclaimer: Shareholders and investors are strongly cautioned against placing undue reliance on information set forth within this website and these communications in making any investment decisions concerning our securities. The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the Company's periodic reports filed with the OTCMarkets.com including the company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.

SOURCE: Atlantic Power and Infrastructure Corp.



View source version on accesswire.com:
https://www.accesswire.com/689931/Atlantic-Power-and-Infrastructures-KB-Industries-FlexiR-Pave-provides-a-Welcome-Solution-for-Pump-Tracks

$AWSL Atlantic Power and Infrastructure’s KB Industries Flexi(R)-Pave provides a Welcome Solution for Pump Tracks
Press Release | 02/23/2022
Atlantic's KB Industries proprietary Flexi®-Pave installation at "Velosolutions Pump Track" installed at Big Rock Quarry in North Little Rock, Arkansas gives wheeled sports fans an ideal facility

TAMPA BAY, FL / ACCESSWIRE / February 23, 2022 / Atlantic Power & Infrastructure Corp. (OTC PINK:AWSL) is pleased to announce it has completed the installation of the recently opened ‘PUMP TRACK' at the popular Big Rock Quarry Bike Park in Little Rock, Arkansas

Flexi®-Pave was chosen to replace the traditional grass or turf, as Flexi®-Pave strong and porous finish provides the necessary drainage, subsequently increasing the rideable surface areas within the Pump Track. Flexi®-Pave is an ideal alternative for landscaping in this application for many reasons. It allows water drainage, provides low to almost no maintenance for city parks, eliminates the need for weed eating or watering grass. The Flexi®-Pave surface is sturdy enough to allow bikes to ride over without damaging the landscaping and to use in tandem with the actual Pump Track course. Installed by https://velosolutions.com/pump-track-races/ who now view Flexi®-Pave as the surface of choice in future installations due to all its benefits and it's pleasing visual appeal.

About Pump Track

Pump Tracks being a track for wheeled sports equipment that, when ridden properly, does not require pedaling or pushing, but a "pumping" action to maintain momentum. Originally designed for the mountain bike and the BMX scene, now, due to improved construction technology, is also used by skateboarders, and accessible to wheelchairs.

In 2018, Velosolutions in conjunction with Red Bull launched the first global pump track race series, the Red Bull Pump Track World Championships. In 2019 the winning podium included a UCI Gold Medal after joining forces with the Union Cycliste Internationale and became the Red Bull UCI Pump Track World Championships. The future holds the Olympics in its sights and the future sure looks bright.

Learn more at: https://velosolutions.com/pump-track-races/

Big Rock Quarry Park


North Little Rock Parks and Recreation is located at Big Rock Quarry Bike Park, 4000 River Road • North Little Rock, Arkansas. http://nlrpr.org/parks/big_rock_quarry_park

(Installation of Flexi®-Pave not yet shown on their website)

About Flexi®-Pave

Flexi®-Pave uses the natural, vulcanized strength of scrap tires, along with KBI's proprietary technology, and converts the "Recycled Tire Granules" into proven, sustainable infrastructure construction products. This massively porous but strong structural material can be used for a variety of infrastructure applications with demonstrated success. Applications include storm water management, water treatment and shoreline protection projects, including ship docks. Flexi®-Pave offers long and short-term permeability, flexibility, crack resistance (even freeze-thaw conditions) trip hazard resistance and slip resistance. Notable locations include Yellowstone National Park; Arlington National Cemetery; Seaside Park's Band Shell, City of Bridgeport, Connecticut; Red Butte Gardens, Utah; Atlanta Georgia's Iconic Beltline; Kew Botanical Gardens, London England.

About Atlantic Power and Infrastructure Corp.

Atlantic P&I provides environmental technologies including converting recycled tire material into proven, sustainable infrastructure products. Its flagship product Flexi ® -Pave's resounding strength, flexibility and porous nature which protects from land erosion has led to its use in high profile shoreline break walls and other marine and infrastructure projects. The Company's water purification technology removes harmful algae blooms from freshwater rivers and lakes, and Red Tide algae blooms from salt water. The Company further plans to utilize its existing bi-products and relationships to produce waste to energy power generation.

Submit enquires to:

enquiries@apaicorp.com
Visit: www.AtlanticPIC.com
Tel. ++1 (727) 723-3300

Disclaimer: Shareholders and investors are strongly cautioned against placing undue reliance on information set forth within this website and these communications in making any investment decisions concerning our securities. The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the Company's periodic reports filed with the OTCMarkets.com including the company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.

SOURCE: Atlantic Power and Infrastructure Corp.



View source version on accesswire.com:
https://www.accesswire.com/689931/Atlantic-Power-and-Infrastructures-KB-Industries-FlexiR-Pave-provides-a-Welcome-Solution-for-Pump-Tracks

$MAPT Maptelligent is Pleased to Announce Its New Strategic Focus, Implementing the Latest in Location Intelligence Making Indoor Maps More Intelligent
Press Release | 02/23/2022
LAS VEGAS, NV, Feb. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Maptelligent, Inc., (OTC PK: MAPT) www.maptelligent.com, its where indoor maps become intelligent. Maptelligent, Inc., has a new strategic focus, implementing innovative technology, allowing customers to model their operations and solve today’s complex business problems. Using the latest in remote capture technology (LIDAR, Photogrammetry), building information, modeling and location intelligence delivers customized digital twin and Industry 4.0 applications. Maptelligent, Inc., a Silver Partner in the Esri Partner Network (EPN), provides customers a secure web application with a flexible framework on Esri’s ArcGIS Platform technology. Maptelligent, Inc., provides web and mobile solutions that leverage the latest in Esri’s no code/low code development capability. This provides cost effective, customized solutions, which are tailored to our customers' unique disparate data and operational requirements. Coupled with Esri’s ArcGIS GeoBIM and Autodesk Construction Cloud interoperability, the Maptelligent, Inc., Explorer solution delivers an innovative, easy-to-use web-based experience by integrating multiple operations, including asset management, building automation and control, interdisciplinary coordination, scheduling, cost estimating, and integrated construction specifications.

Maptelligent Explorer easily works with disparate data from multiple systems, in configurable web and mobile applications that uncover operational efficiencies. In addition to, direct access to building information models, industrial systems and IoT devices, integrated with existing operations.

Maptelligent, Inc., solutions development staff are trained on Esri’s ArcGIS Platform and exclusively deliver our customers applications using Esri products and Maptelligent, Inc., services. "Implementing the best of breed solutions from Esri allows us to focus on the customer and the customer solution, with confidence on the technology and implementation. I look forward to expanding Esri's ArcGIS Platform to our customer base," says Joseph Cosio-Barron, President and CEO of Maptelligent, Inc.

“I look forward to seeing the results of the new strategic focus of Maptelligent,” said Christina Sullivan, Head of Strategic Marketing: Partners and Alliances at Esri. “The focus they have on ArcGIS Platform will allow them to provide customers with solutions based on Esri’s latest technology.”

About Esri

Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com.

About Maptelligent, Inc.

Maptelligent, Inc.’s mission is to provide information and data interoperability enabling organizations to quickly share information during a time of crisis. Maptelligent, Inc., provides a geographic platform to access site-specific information enhancing physical security and facility management. Maptelligent, Inc., continues its dedication to bringing the latest in custom configured, geo-enabled, indoor mapping applications to the market. The integrated solutions provide the latest in disparate data interoperability and real-time actionable intelligence to customers on their operations. Maptelligent, Inc., creates interactive, dynamic digital floorplans that have a quick learning curve and were designed for non-technical users.

Contact Website:
https://www.maptelligent.com
info@maptelligent.com

Contact: Joseph Cosio-Barron CEO 415 990-8141

$MAPT Maptelligent is Pleased to Announce Its New Strategic Focus, Implementing the Latest in Location Intelligence Making Indoor Maps More Intelligent
Press Release | 02/23/2022
LAS VEGAS, NV, Feb. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Maptelligent, Inc., (OTC PK: MAPT) www.maptelligent.com, its where indoor maps become intelligent. Maptelligent, Inc., has a new strategic focus, implementing innovative technology, allowing customers to model their operations and solve today’s complex business problems. Using the latest in remote capture technology (LIDAR, Photogrammetry), building information, modeling and location intelligence delivers customized digital twin and Industry 4.0 applications. Maptelligent, Inc., a Silver Partner in the Esri Partner Network (EPN), provides customers a secure web application with a flexible framework on Esri’s ArcGIS Platform technology. Maptelligent, Inc., provides web and mobile solutions that leverage the latest in Esri’s no code/low code development capability. This provides cost effective, customized solutions, which are tailored to our customers' unique disparate data and operational requirements. Coupled with Esri’s ArcGIS GeoBIM and Autodesk Construction Cloud interoperability, the Maptelligent, Inc., Explorer solution delivers an innovative, easy-to-use web-based experience by integrating multiple operations, including asset management, building automation and control, interdisciplinary coordination, scheduling, cost estimating, and integrated construction specifications.

Maptelligent Explorer easily works with disparate data from multiple systems, in configurable web and mobile applications that uncover operational efficiencies. In addition to, direct access to building information models, industrial systems and IoT devices, integrated with existing operations.

Maptelligent, Inc., solutions development staff are trained on Esri’s ArcGIS Platform and exclusively deliver our customers applications using Esri products and Maptelligent, Inc., services. "Implementing the best of breed solutions from Esri allows us to focus on the customer and the customer solution, with confidence on the technology and implementation. I look forward to expanding Esri's ArcGIS Platform to our customer base," says Joseph Cosio-Barron, President and CEO of Maptelligent, Inc.

“I look forward to seeing the results of the new strategic focus of Maptelligent,” said Christina Sullivan, Head of Strategic Marketing: Partners and Alliances at Esri. “The focus they have on ArcGIS Platform will allow them to provide customers with solutions based on Esri’s latest technology.”

About Esri

Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com.

About Maptelligent, Inc.

Maptelligent, Inc.’s mission is to provide information and data interoperability enabling organizations to quickly share information during a time of crisis. Maptelligent, Inc., provides a geographic platform to access site-specific information enhancing physical security and facility management. Maptelligent, Inc., continues its dedication to bringing the latest in custom configured, geo-enabled, indoor mapping applications to the market. The integrated solutions provide the latest in disparate data interoperability and real-time actionable intelligence to customers on their operations. Maptelligent, Inc., creates interactive, dynamic digital floorplans that have a quick learning curve and were designed for non-technical users.

Contact Website:
https://www.maptelligent.com
info@maptelligent.com

Contact: Joseph Cosio-Barron CEO 415 990-8141

$MAPT Maptelligent is Pleased to Announce Its New Strategic Focus, Implementing the Latest in Location Intelligence Making Indoor Maps More Intelligent
Press Release | 02/23/2022
LAS VEGAS, NV, Feb. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Maptelligent, Inc., (OTC PK: MAPT) www.maptelligent.com, its where indoor maps become intelligent. Maptelligent, Inc., has a new strategic focus, implementing innovative technology, allowing customers to model their operations and solve today’s complex business problems. Using the latest in remote capture technology (LIDAR, Photogrammetry), building information, modeling and location intelligence delivers customized digital twin and Industry 4.0 applications. Maptelligent, Inc., a Silver Partner in the Esri Partner Network (EPN), provides customers a secure web application with a flexible framework on Esri’s ArcGIS Platform technology. Maptelligent, Inc., provides web and mobile solutions that leverage the latest in Esri’s no code/low code development capability. This provides cost effective, customized solutions, which are tailored to our customers' unique disparate data and operational requirements. Coupled with Esri’s ArcGIS GeoBIM and Autodesk Construction Cloud interoperability, the Maptelligent, Inc., Explorer solution delivers an innovative, easy-to-use web-based experience by integrating multiple operations, including asset management, building automation and control, interdisciplinary coordination, scheduling, cost estimating, and integrated construction specifications.

Maptelligent Explorer easily works with disparate data from multiple systems, in configurable web and mobile applications that uncover operational efficiencies. In addition to, direct access to building information models, industrial systems and IoT devices, integrated with existing operations.

Maptelligent, Inc., solutions development staff are trained on Esri’s ArcGIS Platform and exclusively deliver our customers applications using Esri products and Maptelligent, Inc., services. "Implementing the best of breed solutions from Esri allows us to focus on the customer and the customer solution, with confidence on the technology and implementation. I look forward to expanding Esri's ArcGIS Platform to our customer base," says Joseph Cosio-Barron, President and CEO of Maptelligent, Inc.

“I look forward to seeing the results of the new strategic focus of Maptelligent,” said Christina Sullivan, Head of Strategic Marketing: Partners and Alliances at Esri. “The focus they have on ArcGIS Platform will allow them to provide customers with solutions based on Esri’s latest technology.”

About Esri

Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com.

About Maptelligent, Inc.

Maptelligent, Inc.’s mission is to provide information and data interoperability enabling organizations to quickly share information during a time of crisis. Maptelligent, Inc., provides a geographic platform to access site-specific information enhancing physical security and facility management. Maptelligent, Inc., continues its dedication to bringing the latest in custom configured, geo-enabled, indoor mapping applications to the market. The integrated solutions provide the latest in disparate data interoperability and real-time actionable intelligence to customers on their operations. Maptelligent, Inc., creates interactive, dynamic digital floorplans that have a quick learning curve and were designed for non-technical users.

Contact Website:
https://www.maptelligent.com
info@maptelligent.com

Contact: Joseph Cosio-Barron CEO 415 990-8141

$AVRN Avra, Inc. Operating as Springs Rejuvenation (AVRN) Reports a +200% Increase in Revenue Post-Merger
Press Release | 02/22/2022
ATLANTA, GA, Feb. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Avra, Inc. (OTC PINK: AVRN), operating as Springs Rejuvenation, (“Springs”), a Chamblee, Georgia based anti-aging and stem cell center focusing on stem cell therapy, announced today a +200% increase in their 4th quarter earnings compared to the 3rd quarter. This is a substantial increase nearly matching All of the 3 previous quarters’ earnings combined, and strong growth is expected to continue. Avra’s annual report, filed on OTC Markets, shows a strong uptick of the company’s earnings post-merger.

CEO Everett Dickson is quoted as saying, “It’s clear our marketing efforts are beginning to bear fruit. We have been retooling our digital footprint, beta testing several Google ads and launching a ‘boots on the ground’ campaign to increase the recognition of our clinics. We expect this trend to increase as our new locations open and our new C-Arm equipment expands our service offerings.”

About Springs Rejuvenation Inc.

At Springs Rejuvenation, we strive to be at the cutting edge of regenerative medicine and anti-aging research. Our mission is to provide patients with individualized, state-of-the-art treatment, returning each patient to their natural mobility as quickly as possible.

Our goal is to address the root cause of a patient’s pain, rather than just masking it. We want to help patients achieve whole body health and rejuvenation. This will help them feel stronger, improve mood, look younger, heal faster, and perform at the optimal level. Our patients have found both freedom from pain and improved quality of life.

Our professional staff is uniquely composed of physicians/researchers in the Stem Cell, Anti-Aging research and regenerative medicine, also including sports-related injuries and chronic joint pain.

Our Medical Director & Founder is Dr. Charles A. Pereyra,the founder of Springs Rejuvenation Stem Cell Therapy in Atlanta, GA (since 2018). He is our current lead clinical Physician and an expert in Stem Cell, Anti-Aging research and Regenerative medicine. Dr. Juan Pablo Nieto specializes in sports-related injuries as well as chronic joint pain. Dr. Nieto has expertise and significant experience with diagnostic ultrasound exams as well as joint and tendon injections with PRP, & prolotherapy. His highlights include caring/treating professional athletes: NBA Wizards & D1 level athletes from different multiple sports and presented research at national conferences.

FORWARD-LOOKING STATEMENTS:

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For a discussion of these risks and uncertainties, please see our filings with the OTC Markets Group Inc. Our public filings with the OTC Markets Group Inc are available from commercial document retrieval services and at the website maintained by the OTC Markets at https://www.otcmarkets.com/stock/AVRN/disclosure

Company website(s): www.avrabiz.com ; https://springsrejuvenation.com

Company Twitter: @Springsavra

Email: avrabiz21@gmail.com

Phone: 678-387-3515

$AVRN Avra, Inc. Operating as Springs Rejuvenation (AVRN) Reports a +200% Increase in Revenue Post-Merger
Press Release | 02/22/2022
ATLANTA, GA, Feb. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Avra, Inc. (OTC PINK: AVRN), operating as Springs Rejuvenation, (“Springs”), a Chamblee, Georgia based anti-aging and stem cell center focusing on stem cell therapy, announced today a +200% increase in their 4th quarter earnings compared to the 3rd quarter. This is a substantial increase nearly matching All of the 3 previous quarters’ earnings combined, and strong growth is expected to continue. Avra’s annual report, filed on OTC Markets, shows a strong uptick of the company’s earnings post-merger.

CEO Everett Dickson is quoted as saying, “It’s clear our marketing efforts are beginning to bear fruit. We have been retooling our digital footprint, beta testing several Google ads and launching a ‘boots on the ground’ campaign to increase the recognition of our clinics. We expect this trend to increase as our new locations open and our new C-Arm equipment expands our service offerings.”

About Springs Rejuvenation Inc.

At Springs Rejuvenation, we strive to be at the cutting edge of regenerative medicine and anti-aging research. Our mission is to provide patients with individualized, state-of-the-art treatment, returning each patient to their natural mobility as quickly as possible.

Our goal is to address the root cause of a patient’s pain, rather than just masking it. We want to help patients achieve whole body health and rejuvenation. This will help them feel stronger, improve mood, look younger, heal faster, and perform at the optimal level. Our patients have found both freedom from pain and improved quality of life.

Our professional staff is uniquely composed of physicians/researchers in the Stem Cell, Anti-Aging research and regenerative medicine, also including sports-related injuries and chronic joint pain.

Our Medical Director & Founder is Dr. Charles A. Pereyra,the founder of Springs Rejuvenation Stem Cell Therapy in Atlanta, GA (since 2018). He is our current lead clinical Physician and an expert in Stem Cell, Anti-Aging research and Regenerative medicine. Dr. Juan Pablo Nieto specializes in sports-related injuries as well as chronic joint pain. Dr. Nieto has expertise and significant experience with diagnostic ultrasound exams as well as joint and tendon injections with PRP, & prolotherapy. His highlights include caring/treating professional athletes: NBA Wizards & D1 level athletes from different multiple sports and presented research at national conferences.

FORWARD-LOOKING STATEMENTS:

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For a discussion of these risks and uncertainties, please see our filings with the OTC Markets Group Inc. Our public filings with the OTC Markets Group Inc are available from commercial document retrieval services and at the website maintained by the OTC Markets at https://www.otcmarkets.com/stock/AVRN/disclosure

Company website(s): www.avrabiz.com ; https://springsrejuvenation.com

Company Twitter: @Springsavra

Email: avrabiz21@gmail.com

Phone: 678-387-3515

$XALL Xalles Establishes Its First Artificial Intelligence Business Relationship
Press Release | 02/22/2022
Xalles Plans to Implement AI Tools to Optimize the Fintech Ecosystem

WASHINGTON, DC, Feb. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Xalles Holdings Inc. (OTC: XALL), a fintech holding company providing innovative technology and financial services solutions, today announces that Xalles Technology it has executed a marketing agreement with Salesmaster ai to refer clients to implement an innovative suite of sales and marketing artificial intelligence services.

Xalles Technology Inc., a wholly owned subsidiary of Xalles Holdings Inc., and Salesmaster ai, a Florida-based artificial intelligence company, will work together to implement sales and marketing AI solutions for Xalles clients and prospects, within the financial services industry and within other vertical markets. The existing solutions available include using AI in real-time for digital advertising without the use of cookies or data retention, lead generation and more through an AI-driven 'Infrastructure as a Solution'.

“The Xalles management team believes that artificial intelligence is the next major long-term trend in system solutions that will support improving a wide variety of processes,” stated Thomas Nash, Chairman and CEO of Xalles Holdings Inc. He continued, “We think our AI philosophy and goals are well aligned with Salesmaster ai and we plan to work together to support their existing solutions and develop new AI tools.”

“Salesmaster ai is pleased to be partnered with Xalles and utilize their network to reach more growth-oriented clients,” commented Arturo Del Rio Jr., CEO of Salesmaster ai. He added, “Our AI-based platform has generated terrific returns and cost savings to clients, fueling their ambition for growth.”

About Xalles Holdings Inc.

Xalles Holdings Inc. is a holding company that focuses on the acquisition, alignment, and growth of disruptive fintech companies. The company actively seeks targets in which it can acquire and accelerate market expansion, targeting companies with solid management teams and business models, large total attainable markets (TAM), and lucrative exit opportunities. The company places emphasis on leveraging blockchain technologies to provide industry-leading financial solutions, which, over time, will allow for the capture of recurring revenue streams. For more information, visit our website at www.xalles.com.

About Salesmaster ai

Salesmaster ai is a 100% remote, global company, all connected through modern technology, our human-powered, AI-driven 'Infrastructure as a Solution' helps committed partners make the impact they've always envisioned. The growth process is simplified and optimized through the power of our AI-driven infrastructure and all-in-one platform. Salesmaster ai will help you to thrive. Our suite of AI Growth Tools will make that a reality by systematizing the entire, end-to-end sales and marketing process. For more information, visit our website at www.salesmaster.ai

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov and in OTC Markets at www.otcmarkets.com.

Investor Relations Contacts:
info@xalles.com
202.595.1299 Office

$XALL Xalles Establishes Its First Artificial Intelligence Business Relationship
Press Release | 02/22/2022
Xalles Plans to Implement AI Tools to Optimize the Fintech Ecosystem

WASHINGTON, DC, Feb. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Xalles Holdings Inc. (OTC: XALL), a fintech holding company providing innovative technology and financial services solutions, today announces that Xalles Technology it has executed a marketing agreement with Salesmaster ai to refer clients to implement an innovative suite of sales and marketing artificial intelligence services.

Xalles Technology Inc., a wholly owned subsidiary of Xalles Holdings Inc., and Salesmaster ai, a Florida-based artificial intelligence company, will work together to implement sales and marketing AI solutions for Xalles clients and prospects, within the financial services industry and within other vertical markets. The existing solutions available include using AI in real-time for digital advertising without the use of cookies or data retention, lead generation and more through an AI-driven 'Infrastructure as a Solution'.

“The Xalles management team believes that artificial intelligence is the next major long-term trend in system solutions that will support improving a wide variety of processes,” stated Thomas Nash, Chairman and CEO of Xalles Holdings Inc. He continued, “We think our AI philosophy and goals are well aligned with Salesmaster ai and we plan to work together to support their existing solutions and develop new AI tools.”

“Salesmaster ai is pleased to be partnered with Xalles and utilize their network to reach more growth-oriented clients,” commented Arturo Del Rio Jr., CEO of Salesmaster ai. He added, “Our AI-based platform has generated terrific returns and cost savings to clients, fueling their ambition for growth.”

About Xalles Holdings Inc.

Xalles Holdings Inc. is a holding company that focuses on the acquisition, alignment, and growth of disruptive fintech companies. The company actively seeks targets in which it can acquire and accelerate market expansion, targeting companies with solid management teams and business models, large total attainable markets (TAM), and lucrative exit opportunities. The company places emphasis on leveraging blockchain technologies to provide industry-leading financial solutions, which, over time, will allow for the capture of recurring revenue streams. For more information, visit our website at www.xalles.com.

About Salesmaster ai

Salesmaster ai is a 100% remote, global company, all connected through modern technology, our human-powered, AI-driven 'Infrastructure as a Solution' helps committed partners make the impact they've always envisioned. The growth process is simplified and optimized through the power of our AI-driven infrastructure and all-in-one platform. Salesmaster ai will help you to thrive. Our suite of AI Growth Tools will make that a reality by systematizing the entire, end-to-end sales and marketing process. For more information, visit our website at www.salesmaster.ai

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov and in OTC Markets at www.otcmarkets.com.

Investor Relations Contacts:
info@xalles.com
202.595.1299 Office

$ISWH ISW Holdings Officially Launches Live Mining Operations for its 200MW Southeastern US Bitcoin Mining and Hosting Project
Press Release | 02/22/2022
HOUSTON, TEXAS, Feb. 22, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- ISW Holdings, Inc. (OTC: ISWH) (“ISW Holdings” or the “Company”), a Texas-based portfolio company with primary commercial-stage operations in Cryptocurrency Mining, is pleased to update current and prospective shareholders as the Company begins live mining and hosting operations for its 200-megawatt (“MW”) Bitcoin mining and hosting project.

In partnership with Bit5ive, LLC (“Bit5ive”), and Bitmain Technologies Ltd. (“BITMAIN”), the company has already powered up the first eight (8) POD5 units at the site. Each POD5 unit contains 280 mining rigs now actively mining Bitcoin.

“This is a tremendous day for ISW Holdings and our shareholders,” stated Alonzo Pierce, President and Chair of ISW Holdings. “After months of hard work, and after overcoming a series of obstacles related to the unpredictable global macroeconomic context, we are very proud to announce that the Company is now officially hosting client mining services and mining Bitcoin at scale in our 200MW mining and hosting project.”

Once fully completed, at current energy price spreads and agreements, this first 20MW Phase is expected to generate nearly $9 million in annualized revenues for the Company. Management expects to begin building out phases 2 thru 10 starting in April, targeting 200MW of power across 200 POD5 units, each driving 280 state-of-the-art mining rigs, by January 2023.

Pierce added, “We are now in the process of deploying the first 20MW Phase 1 buildout. We will continue to energize the entire Phase 1 project over the next couple of weeks and then swiftly move on to Phase 2.”

About ISW Holdings
ISW Holdings is an American cryptocurrency mining company supporting blockchain infrastructures that operate globally. As one of the fastest growing crypto mining and mine hosting providers in America, ISW Holdings is quickly transforming the decentralized finance (DeFi) and blockchain industries. The Company provides low cost, sustainable solutions to the cryptocurrency mining ecosystem.

ISW Holdings utilizes scalable blockchain infrastructure to convert unique identifiable assets (UIAs) into interchangeable digital assets such as Bitcoin and other types of fungible digital assets. Offering immediate liquidity in the form of fast, confidential transactions, as well as the issuance of assets in the traditional capital markets.

The Company focuses on hosting and mining Bitcoin with eyes on new IP in Crypto and Blockchain, and currently leases and operates renewable energy power generation facilities in Gaffney, SC.

ISW Holdings is vertically integrated and maintains a fleet of digital/cryptocurrency mining equipment and infrastructure. Based on current partnerships, agreements, and memorandums, the Company anticipates future operations that leverage up to 56,840 crypto asset mining computers (miners).

The Company's Hosting and Mining Operations fleet currently comprises approximately 300 Bitmain Antminer S17 Pro (S17 Pro) miners, approximately 150 Bitmain Antminer S19 (95T) miners, approximately 250 Canaan AvalonMiner 1296 Pro (90T) miners, and approximately 5,600 series S19 J Pro (100-110T) miners per 20 MW of implemented power up to 56,000 S19 J Pro miners for our 200 MW project in partnership with BITMAIN Technologies.

Forward Looking Statements

This press release may contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology including "could", "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" and the negative of these terms or other comparable terminology. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this report. Except as required by applicable law, we do not intend to update any of the forward-looking statements so as to conform these statements to actual results. Investors should refer to the risks disclosed in the Company's reports filed from time to time with OTC Markets (www.otcmarkets.com).

Company Contact:
info@ISWHoldings.com


Public Relations
EDM Media, LLC
https://edm.media

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

$ISWH ISW Holdings Officially Launches Live Mining Operations for its 200MW Southeastern US Bitcoin Mining and Hosting Project
Press Release | 02/22/2022
HOUSTON, TEXAS, Feb. 22, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- ISW Holdings, Inc. (OTC: ISWH) (“ISW Holdings” or the “Company”), a Texas-based portfolio company with primary commercial-stage operations in Cryptocurrency Mining, is pleased to update current and prospective shareholders as the Company begins live mining and hosting operations for its 200-megawatt (“MW”) Bitcoin mining and hosting project.

In partnership with Bit5ive, LLC (“Bit5ive”), and Bitmain Technologies Ltd. (“BITMAIN”), the company has already powered up the first eight (8) POD5 units at the site. Each POD5 unit contains 280 mining rigs now actively mining Bitcoin.

“This is a tremendous day for ISW Holdings and our shareholders,” stated Alonzo Pierce, President and Chair of ISW Holdings. “After months of hard work, and after overcoming a series of obstacles related to the unpredictable global macroeconomic context, we are very proud to announce that the Company is now officially hosting client mining services and mining Bitcoin at scale in our 200MW mining and hosting project.”

Once fully completed, at current energy price spreads and agreements, this first 20MW Phase is expected to generate nearly $9 million in annualized revenues for the Company. Management expects to begin building out phases 2 thru 10 starting in April, targeting 200MW of power across 200 POD5 units, each driving 280 state-of-the-art mining rigs, by January 2023.

Pierce added, “We are now in the process of deploying the first 20MW Phase 1 buildout. We will continue to energize the entire Phase 1 project over the next couple of weeks and then swiftly move on to Phase 2.”

About ISW Holdings
ISW Holdings is an American cryptocurrency mining company supporting blockchain infrastructures that operate globally. As one of the fastest growing crypto mining and mine hosting providers in America, ISW Holdings is quickly transforming the decentralized finance (DeFi) and blockchain industries. The Company provides low cost, sustainable solutions to the cryptocurrency mining ecosystem.

ISW Holdings utilizes scalable blockchain infrastructure to convert unique identifiable assets (UIAs) into interchangeable digital assets such as Bitcoin and other types of fungible digital assets. Offering immediate liquidity in the form of fast, confidential transactions, as well as the issuance of assets in the traditional capital markets.

The Company focuses on hosting and mining Bitcoin with eyes on new IP in Crypto and Blockchain, and currently leases and operates renewable energy power generation facilities in Gaffney, SC.

ISW Holdings is vertically integrated and maintains a fleet of digital/cryptocurrency mining equipment and infrastructure. Based on current partnerships, agreements, and memorandums, the Company anticipates future operations that leverage up to 56,840 crypto asset mining computers (miners).

The Company's Hosting and Mining Operations fleet currently comprises approximately 300 Bitmain Antminer S17 Pro (S17 Pro) miners, approximately 150 Bitmain Antminer S19 (95T) miners, approximately 250 Canaan AvalonMiner 1296 Pro (90T) miners, and approximately 5,600 series S19 J Pro (100-110T) miners per 20 MW of implemented power up to 56,000 S19 J Pro miners for our 200 MW project in partnership with BITMAIN Technologies.

Forward Looking Statements

This press release may contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology including "could", "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" and the negative of these terms or other comparable terminology. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this report. Except as required by applicable law, we do not intend to update any of the forward-looking statements so as to conform these statements to actual results. Investors should refer to the risks disclosed in the Company's reports filed from time to time with OTC Markets (www.otcmarkets.com).

Company Contact:
info@ISWHoldings.com


Public Relations
EDM Media, LLC
https://edm.media

Corporate Communications

IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

$HALB Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually
Press Release | 02/22/2022
JACKSON CENTER, PA / ACCESSWIRE / February 22, 2022 / Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases. With the successful elimination of glutamate from cerebral spinal fluid (CSF), Halberd has demonstrated the capability to control each of the top ten neurodegenerative disease-associated antigens. See Table Below. This could lead to an entirely new way of treating PTSD, Traumatic Brain Injury (TBI), Chronic Traumatic Encephalopathy (CTE), Alzheimer's Disease, Parkinson's Disease, Epilepsy and other neurodegenerative diseases. Halberd's unique approach allows for precise control of the level of inflammatory cytokines, proteins, and amino acids in CSF to produce and maintain healthy brain function.


Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "Glutamate is associated with a number of neurodegenerative conditions. Being able to precisely control glutamate levels in a patient would provide a powerful tool in the treatment of these conditions."

Dr. William G. Sturrus, Chairman of the Physics, Astronomy, Geology, and Environmental Science Department at Youngstown State University, who oversees Halberd's patented laser and radio frequency test program, commented, "It is exciting to see a single approach demonstrating such overwhelming success given the large range of antigen sizes addressed. We have experienced complete elimination of all 10 neurodegenerative disease-associated antigens in the lab, and we find elimination occurs in especially short laser exposure times. It is difficult to see how this method could be overlooked as an improved way to treat neurodegenerative diseases."

William A. Hartman, Halberd's Chairman, President & CEO added, "This breakthrough will give hope to the 36 million Americans annually, and the millions more around the world, suffering from some form of neurodegenerative diseases. I am proud of the accomplishments of our team in overcoming various obstacles in eliminating all 10 of the top neurological pathogens. We said we would do it, and we did it!

"Our next initiatives are proving efficacy in blood serum and animal testing. Not missing a step, we are in discussions with a major university that specializes in veterinary medicine to undertake animal testing. We have also contacted several Clinical Research Organizations to investigate FDA certification requirements."

Hartman continued, "As an approved government contractor, we updated our already-approved white paper with the Department of Defense regarding our scientific breakthrough. We similarly informed our NFL representative and NCAA contact to seek their organization's participation in and/or endorsement of our program to develop an efficacious treatment for traumatic brain injuries and the subsequent neurodegenerative diseases that often follow."

To view informative videos on Halberd's work, see:
Dr. Felder interviewed by Alec Torelli (

)
William Hartman interviewed by YSU (https://halberdcorporation.com/wp-content/uploads/2022/02/Alumni-Spotlight-William-A.-Hartman-64.mp4)

To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter: @HalberdC

About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed twenty related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.

$BTDG Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually
Press Release | 02/22/2022
JACKSON CENTER, PA / ACCESSWIRE / February 22, 2022 / Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases. With the successful elimination of glutamate from cerebral spinal fluid (CSF), Halberd has demonstrated the capability to control each of the top ten neurodegenerative disease-associated antigens. See Table Below. This could lead to an entirely new way of treating PTSD, Traumatic Brain Injury (TBI), Chronic Traumatic Encephalopathy (CTE), Alzheimer's Disease, Parkinson's Disease, Epilepsy and other neurodegenerative diseases. Halberd's unique approach allows for precise control of the level of inflammatory cytokines, proteins, and amino acids in CSF to produce and maintain healthy brain function.


Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "Glutamate is associated with a number of neurodegenerative conditions. Being able to precisely control glutamate levels in a patient would provide a powerful tool in the treatment of these conditions."

Dr. William G. Sturrus, Chairman of the Physics, Astronomy, Geology, and Environmental Science Department at Youngstown State University, who oversees Halberd's patented laser and radio frequency test program, commented, "It is exciting to see a single approach demonstrating such overwhelming success given the large range of antigen sizes addressed. We have experienced complete elimination of all 10 neurodegenerative disease-associated antigens in the lab, and we find elimination occurs in especially short laser exposure times. It is difficult to see how this method could be overlooked as an improved way to treat neurodegenerative diseases."

William A. Hartman, Halberd's Chairman, President & CEO added, "This breakthrough will give hope to the 36 million Americans annually, and the millions more around the world, suffering from some form of neurodegenerative diseases. I am proud of the accomplishments of our team in overcoming various obstacles in eliminating all 10 of the top neurological pathogens. We said we would do it, and we did it!

"Our next initiatives are proving efficacy in blood serum and animal testing. Not missing a step, we are in discussions with a major university that specializes in veterinary medicine to undertake animal testing. We have also contacted several Clinical Research Organizations to investigate FDA certification requirements."

Hartman continued, "As an approved government contractor, we updated our already-approved white paper with the Department of Defense regarding our scientific breakthrough. We similarly informed our NFL representative and NCAA contact to seek their organization's participation in and/or endorsement of our program to develop an efficacious treatment for traumatic brain injuries and the subsequent neurodegenerative diseases that often follow."

To view informative videos on Halberd's work, see:
Dr. Felder interviewed by Alec Torelli (

)
William Hartman interviewed by YSU (https://halberdcorporation.com/wp-content/uploads/2022/02/Alumni-Spotlight-William-A.-Hartman-64.mp4)

To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter: @HalberdC

About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed twenty related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.

$HALB Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually
Press Release | 02/22/2022
JACKSON CENTER, PA / ACCESSWIRE / February 22, 2022 / Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases. With the successful elimination of glutamate from cerebral spinal fluid (CSF), Halberd has demonstrated the capability to control each of the top ten neurodegenerative disease-associated antigens. See Table Below. This could lead to an entirely new way of treating PTSD, Traumatic Brain Injury (TBI), Chronic Traumatic Encephalopathy (CTE), Alzheimer's Disease, Parkinson's Disease, Epilepsy and other neurodegenerative diseases. Halberd's unique approach allows for precise control of the level of inflammatory cytokines, proteins, and amino acids in CSF to produce and maintain healthy brain function.


Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "Glutamate is associated with a number of neurodegenerative conditions. Being able to precisely control glutamate levels in a patient would provide a powerful tool in the treatment of these conditions."

Dr. William G. Sturrus, Chairman of the Physics, Astronomy, Geology, and Environmental Science Department at Youngstown State University, who oversees Halberd's patented laser and radio frequency test program, commented, "It is exciting to see a single approach demonstrating such overwhelming success given the large range of antigen sizes addressed. We have experienced complete elimination of all 10 neurodegenerative disease-associated antigens in the lab, and we find elimination occurs in especially short laser exposure times. It is difficult to see how this method could be overlooked as an improved way to treat neurodegenerative diseases."

William A. Hartman, Halberd's Chairman, President & CEO added, "This breakthrough will give hope to the 36 million Americans annually, and the millions more around the world, suffering from some form of neurodegenerative diseases. I am proud of the accomplishments of our team in overcoming various obstacles in eliminating all 10 of the top neurological pathogens. We said we would do it, and we did it!

"Our next initiatives are proving efficacy in blood serum and animal testing. Not missing a step, we are in discussions with a major university that specializes in veterinary medicine to undertake animal testing. We have also contacted several Clinical Research Organizations to investigate FDA certification requirements."

Hartman continued, "As an approved government contractor, we updated our already-approved white paper with the Department of Defense regarding our scientific breakthrough. We similarly informed our NFL representative and NCAA contact to seek their organization's participation in and/or endorsement of our program to develop an efficacious treatment for traumatic brain injuries and the subsequent neurodegenerative diseases that often follow."

To view informative videos on Halberd's work, see:
Dr. Felder interviewed by Alec Torelli (

)
William Hartman interviewed by YSU (https://halberdcorporation.com/wp-content/uploads/2022/02/Alumni-Spotlight-William-A.-Hartman-64.mp4)

To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter: @HalberdC

About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed twenty related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.

$BTDG B2Digital on Pace for Breakout Quarter after Strong January Performance
Press Release | 02/22/2022
TAMPA, FL, Feb. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – B2Digital Incorporated (the “Company” or “B2Digital”) (OTCMKTS:BTDG), the premier development league for mixed martial arts (“MMA”), is pleased to report unaudited performance metrics for January 2022 along with performance projections for the three months ending March 31, 2022.

Note: The following numbers represent unaudited preliminary data subject to potential revision in future financial reporting.
Highlights for January 2022 (unaudited)

Total Revenues of $276k in January, up 45% year over year
Live Event segment grew 22% year over year in January despite staging only 2 events during the month
The B2 Training Facilities segment saw revenues jump by 52% year over year in January, driven by the integration of performance from newly acquired Spartan Fitness
Overall Gross Profit grew 18% year over year in January
Topline Projections for the Three Months Ending March 31, 2022, based on year-to-date performance

Total Revenues of ~$1.1 million, up 142% year over year
Live Event Segment revenues of ~$310k, up 62% year over year, broken down into Gate ticket sales of ~$250k and Pay Per View sales of ~$60k
B2 Training Facilities segment revenues of ~$700k, up 165% year over year, broken down into ONE MORE Gym revenues of ~$360k and Spartan Fitness revenues of ~$340k
“We are off to a tremendous start in 2022 after integrating Spartan as both our live event and training segments fire on all cylinders out of the gates,” remarked Grep P. Bell, CEO of B2 Digital. “Just based on simple extrapolation from what we are seeing, if we drill down into how each piece of the puzzle has performed year to date, we can already start to make some reasonable assumptions about where we will be by the end of March when we wrap up our fiscal year. With Spartan data involved, and current growth rates extending through the quarter, we should be on pace to well more than double what we did last year in fiscal Q4. But the real acceleration should come after that as we continue to roll up new training facility locations and expand our live event geographic footprint through the rest of 2022.”

About B2Digital Inc.

B2Digital (OTC: BTDG) is the premier development league for mixed martial arts (“MMA”). The Company operates in two major branded segments: The B2 Fighting Series and The Official B2 Training Facilities Network, which is comprised of ONE MORE Gym and Spartan Fitness. The Company primarily derives revenues from live event ticket sales, pay-per-view ticket sales, content media marketing, and fitness facility memberships.

The Live Events segment (the B2 Fighting Series) is primarily engaged with scheduling, organizing, and producing live MMA events, marketing those events, and generating both live audience and PPV ticket sales, as well as creatively marketing the archived content generated through its operations in this segment. The Company also plans to generate additional revenues over time from endorsement deals with global brands as its audience grows. The B2 Fighting Series is licensed in 20 US states to operate LIVE MMA Fights. Most B2 Fighting Series events sell out at the gate. The Company now operates at a pace of more than 40 events per year.

The B2 Training Facilities segment operates primarily through its ONE More Gym brand and its Spartan Fitness Facilities brand. The Company currently operates five ONE More Gym locations, with plans to continue to scale up the B2 Training Facilities segment at a pace of 15 new locations over the next 3 years. Both ONE MORE Gym and Spartan Fitness locations include specialized MMA training resources and serve a recruiting function for the Company's Live Events segment.
For more information about B2Digital, visit the Company’s website at www.B2FS.com.

B2Digital has a growing social media presence. Follow us on:

Twitter: @B2digitalOTC

Facebook: https://m.facebook.com/b2digitalotc/

B2Digital: MMA’s Premier Development League
www.B2FS.com

B2 Fighting Series Pay Per View Link
www.b2mma.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Press Release contains forward-looking statements within the meaning of the securities laws. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information, please contact:
information@b2fs.com

Public Relations:
Tiger Marketing & Branding Agency
info@TigerGMP.com

$BTDG B2Digital on Pace for Breakout Quarter after Strong January Performance
Press Release | 02/22/2022
TAMPA, FL, Feb. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – B2Digital Incorporated (the “Company” or “B2Digital”) (OTCMKTS:BTDG), the premier development league for mixed martial arts (“MMA”), is pleased to report unaudited performance metrics for January 2022 along with performance projections for the three months ending March 31, 2022.

Note: The following numbers represent unaudited preliminary data subject to potential revision in future financial reporting.
Highlights for January 2022 (unaudited)

Total Revenues of $276k in January, up 45% year over year
Live Event segment grew 22% year over year in January despite staging only 2 events during the month
The B2 Training Facilities segment saw revenues jump by 52% year over year in January, driven by the integration of performance from newly acquired Spartan Fitness
Overall Gross Profit grew 18% year over year in January
Topline Projections for the Three Months Ending March 31, 2022, based on year-to-date performance

Total Revenues of ~$1.1 million, up 142% year over year
Live Event Segment revenues of ~$310k, up 62% year over year, broken down into Gate ticket sales of ~$250k and Pay Per View sales of ~$60k
B2 Training Facilities segment revenues of ~$700k, up 165% year over year, broken down into ONE MORE Gym revenues of ~$360k and Spartan Fitness revenues of ~$340k
“We are off to a tremendous start in 2022 after integrating Spartan as both our live event and training segments fire on all cylinders out of the gates,” remarked Grep P. Bell, CEO of B2 Digital. “Just based on simple extrapolation from what we are seeing, if we drill down into how each piece of the puzzle has performed year to date, we can already start to make some reasonable assumptions about where we will be by the end of March when we wrap up our fiscal year. With Spartan data involved, and current growth rates extending through the quarter, we should be on pace to well more than double what we did last year in fiscal Q4. But the real acceleration should come after that as we continue to roll up new training facility locations and expand our live event geographic footprint through the rest of 2022.”

About B2Digital Inc.

B2Digital (OTC: BTDG) is the premier development league for mixed martial arts (“MMA”). The Company operates in two major branded segments: The B2 Fighting Series and The Official B2 Training Facilities Network, which is comprised of ONE MORE Gym and Spartan Fitness. The Company primarily derives revenues from live event ticket sales, pay-per-view ticket sales, content media marketing, and fitness facility memberships.

The Live Events segment (the B2 Fighting Series) is primarily engaged with scheduling, organizing, and producing live MMA events, marketing those events, and generating both live audience and PPV ticket sales, as well as creatively marketing the archived content generated through its operations in this segment. The Company also plans to generate additional revenues over time from endorsement deals with global brands as its audience grows. The B2 Fighting Series is licensed in 20 US states to operate LIVE MMA Fights. Most B2 Fighting Series events sell out at the gate. The Company now operates at a pace of more than 40 events per year.

The B2 Training Facilities segment operates primarily through its ONE More Gym brand and its Spartan Fitness Facilities brand. The Company currently operates five ONE More Gym locations, with plans to continue to scale up the B2 Training Facilities segment at a pace of 15 new locations over the next 3 years. Both ONE MORE Gym and Spartan Fitness locations include specialized MMA training resources and serve a recruiting function for the Company's Live Events segment.
For more information about B2Digital, visit the Company’s website at www.B2FS.com.

B2Digital has a growing social media presence. Follow us on:

Twitter: @B2digitalOTC

Facebook: https://m.facebook.com/b2digitalotc/

B2Digital: MMA’s Premier Development League
www.B2FS.com

B2 Fighting Series Pay Per View Link
www.b2mma.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Press Release contains forward-looking statements within the meaning of the securities laws. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information, please contact:
information@b2fs.com

Public Relations:
Tiger Marketing & Branding Agency
info@TigerGMP.com

$ITMZF REPEAT – Intema closes Livestream Gaming acquisition in escrow
Press Release | 02/22/2022
The Corporation satisfies conditions to acquire Livestream Gaming and triggers automatic exercise of subscription receipts into common shares and warrants of Intema.

Livestream Gaming is the parent company of LOOT.BET, a top online gaming platform and brand in the esports betting space.

The acquisition will be accretive to Intema’s revenues: Livestream Gaming recorded gross gaming revenue of 2.2 million euros for the year ended December 31, 2021 (3.2 million euros in 2020).

LOOT.BET will benefit from the recently granted Isle of Man online gaming license and Intema’s growing esports and iGaming ecosystem.
MONTREAL, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Intema Solutions Inc. (“Intema” or the “Corporation”) (TSXV: ITM, OTCMKTS: ITMZF) is pleased to announce that the Corporation has satisfied the outstanding conditions for the release of the escrowed funds from the Corporation's previously announced C$10.007 million private placement (the "Offering") of subscription receipts (the "Subscription Receipts").

The Corporation is also very pleased to announce that it has closed its previously announced transaction with Livestream Gaming Ltd (“Livestream”), whereby Intema has acquired all of the issued and outstanding securities in the capital of Livestream (the “Transaction”). The Consideration (as defined herein) will be held in escrow pending posting of the filing statement on SEDAR and issuance of the TSX Venture Exchange bulletin about the Transaction. Livestream is the parent company of LOOT.BET, a licensed server-based real-money online gaming platform and a top brand in the esports betting space. For the year ended December 31, 2021, Livestream recorded gross gaming revenue of 2.2 million euros (3.2 million euros in 2020) and a net loss of 173,818 euros (net loss of 113,808 euros in 2020) as per the draft audited statements, mainly from gamers in Europe and Asia.

“This is a great day for Intema as LOOT.BET is an important steppingstone for us in the esports and iGaming sectors,” said Laurent Benezra, President and CEO of Intema. “I would like to thank our shareholders, investors, employees and stakeholders for their overwhelming support and patience in closing this game-changing acquisition. In our view, LOOT.BET’s online gaming platform is second to none and has great market and scaling potential. With the Isle of Man online gaming license in place, LOOT.BET is well positioned to expand its operations globally, which enables us to accelerate our expansion. Over the last year, Intema’s team has been working hard in parallel to build our esports and iGaming ecosystem in anticipation of this very moment, and we look forward to sharing our progress as we continue to expand our activities and focus on achieving profitable growth.”

Closing of the Transaction

In connection with the escrow release, the 20,014,000 Subscription Receipts issued pursuant to the Offering will be automatically exercised into 20,014,000 common shares of the Corporation (each, a "Common Share") and 10,007,000 common share purchase warrants of the Corporation (each, a "Warrant") for gross proceeds of C$10.007 million. Each Warrant entitles the holder thereof to purchase one Common Share at an exercise price of $0.90 for a period of 12 months from the date of issuance.

It is expected that the Corporation will use a portion of the escrowed proceeds to fund the cash consideration (the "Cash Consideration") payable to the vendors in connection with the Transaction. In connection with the closing of the Transaction, the Corporation also issued 6,470,588 Common Shares at a deemed price of $0.425 per Share to the vendors (together with the Cash Consideration, the "Consideration").

In connection with the Private Placement, the Corporation paid to eligible arm’s length parties (each a “Finder”): (i) an aggregate cash fee $383,695; and (ii) 1,019,921 Finders warrants (each a “Finder Warrant”). Each Finder Warrant will be exercisable into one additional common share at an exercise price of $0.90 per share for a period of 12 months from the closing of the Transaction.

All securities issued pursuant to the Transaction and the Finder Warrants are subject to a statutory hold period of four months and one day, expiring on June 19, 2022.

Certain insiders of the Corporation subscribed for 1,186,000 Subscription Receipts under the Offering and such transaction is considered to be a “related party transaction” as defined under Multilateral Instrument 61-101 (“MI 61-101”). The transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of any securities issued to or the consideration paid exceeded 25% of the Corporation’s market capitalization.

Grant of Options

Lastly the Corporation’s board of directors has approved the grant of stock options (the “Options”) exercisable for a total of 6,029,412 common shares (“Common Shares”) to its directors, officers, employees and consultants. All Options were granted pursuant to the Corporation’s stock option plan and are subject to the terms of the applicable grant agreements and the requirements of the TSX Venture Exchange.

The Options were granted at an exercise price of $0.50. 3,529,412 Options shall expire on February 18, 2024, and 2,500,000 Options shall expire on February 18, 2027.

Share issuance to Agora
Further to its news release of April 21, 2021, on January 12, 2022, Intema issued an aggregate of 59,154 common shares of the Corporation at a deemed price of $0.355 per share to Agora Internet Relations Corp. in consideration of services rendered.

About LOOT.BET
LOOT.BET is one of the global leaders in esports betting, with a focus on live betting and online gaming and building an exceptional product for its 450,000+ registered users. Supported by a professional operational and software development team of over 50 employees, LOOT.BET is world-renowned not only as an established and reliable esports betting platform but also as a supporter of the esports industry. It is a regular sponsor of notable professional tournaments and teams and a partner of leading esports operators, studios and bright esports talents and influencers. It is also a proud supporter of the anti-corruption esports Integrity Commission, helping the organization combat match-fixing and betting fraud, thereby contributing to the development and maturing of both the esports and the esports betting industries. For more information, please visit LOOT.BET.

About Intema
Intema Solutions Inc. is the emerging world leader in the esports and iGaming industry. Our mission is to bring the excitement of esports betting to the entire world through fully licensed, secure online platforms. Our ecosystem consists of subsidiaries in esports, iGaming, product branding, digital advertising and marketing campaign design that are all complementary drivers of our future revenue growth. For more information, please visit our corporate website at intema.ca.

Contact
Laurent Benezra
President and CEO
514-861-1881
info@intema.ca

Forward-Looking Statements
This press release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements” within the meaning of applicable Canadian securities laws. All statements, other than statements of historical facts, included in this press release, including, without limitation, those regarding the Private Placement; the expected development of the Corporation’s business and projects; execution of the Corporation’s vision and growth strategy; sources and availability of financing for the Corporation’s projects; and future liquidity, working capital, and capital requirements, are forward-looking statements. Although the forward-looking statements in this press release are based upon what management of the Corporation believes are reasonable assumptions, they are inherently subject to significant business, economic and competitive uncertainties, and contingencies, and there can be no assurance that they will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-Looking statements can generally be identified by the use of forward-looking words such as “may”, “should”, “will”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this press release relate to, among other things, statements relating to the terms of the Private Placement and the terms of the Proposed Transaction; Intema’s future outlook and anticipated events or results; and the completion of the Private Placement and the Proposed Transaction. Actual future results may differ materially. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause future results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. The Corporation’s statements expressed or implied by these forward-looking statements are subject to a number of risks, uncertainties, and conditions, many of which are outside of the Corporation’s control, and undue reliance should not be placed on such statements. Forward-looking statements are qualified in their entirety by the inherent risks and uncertainties surrounding the Private Placement and the Proposed Transaction, including: that the Corporation’s assumptions in making forward-looking statements may prove to be incorrect; general adverse market conditions and competition; the inability to finance operations and/or obtain any future strategic investment necessary to implement new technologies; the inability to build a sustainable, conscientious company with a stronger presence online through new products in esports and gaming; the inability to obtain, or maintain, gaming license(s); and that market conditions related to the COVID-19 pandemic may negatively affect the outcome of the business or operations of the Corporation, including its results and financial condition. Except as required by securities law, the Corporation does not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. The Corporation undertakes no obligation to update forward-looking statements except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

$ITMZF REPEAT – Intema closes Livestream Gaming acquisition in escrow
Press Release | 02/22/2022
The Corporation satisfies conditions to acquire Livestream Gaming and triggers automatic exercise of subscription receipts into common shares and warrants of Intema.

Livestream Gaming is the parent company of LOOT.BET, a top online gaming platform and brand in the esports betting space.

The acquisition will be accretive to Intema’s revenues: Livestream Gaming recorded gross gaming revenue of 2.2 million euros for the year ended December 31, 2021 (3.2 million euros in 2020).

LOOT.BET will benefit from the recently granted Isle of Man online gaming license and Intema’s growing esports and iGaming ecosystem.
MONTREAL, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Intema Solutions Inc. (“Intema” or the “Corporation”) (TSXV: ITM, OTCMKTS: ITMZF) is pleased to announce that the Corporation has satisfied the outstanding conditions for the release of the escrowed funds from the Corporation's previously announced C$10.007 million private placement (the "Offering") of subscription receipts (the "Subscription Receipts").

The Corporation is also very pleased to announce that it has closed its previously announced transaction with Livestream Gaming Ltd (“Livestream”), whereby Intema has acquired all of the issued and outstanding securities in the capital of Livestream (the “Transaction”). The Consideration (as defined herein) will be held in escrow pending posting of the filing statement on SEDAR and issuance of the TSX Venture Exchange bulletin about the Transaction. Livestream is the parent company of LOOT.BET, a licensed server-based real-money online gaming platform and a top brand in the esports betting space. For the year ended December 31, 2021, Livestream recorded gross gaming revenue of 2.2 million euros (3.2 million euros in 2020) and a net loss of 173,818 euros (net loss of 113,808 euros in 2020) as per the draft audited statements, mainly from gamers in Europe and Asia.

“This is a great day for Intema as LOOT.BET is an important steppingstone for us in the esports and iGaming sectors,” said Laurent Benezra, President and CEO of Intema. “I would like to thank our shareholders, investors, employees and stakeholders for their overwhelming support and patience in closing this game-changing acquisition. In our view, LOOT.BET’s online gaming platform is second to none and has great market and scaling potential. With the Isle of Man online gaming license in place, LOOT.BET is well positioned to expand its operations globally, which enables us to accelerate our expansion. Over the last year, Intema’s team has been working hard in parallel to build our esports and iGaming ecosystem in anticipation of this very moment, and we look forward to sharing our progress as we continue to expand our activities and focus on achieving profitable growth.”

Closing of the Transaction

In connection with the escrow release, the 20,014,000 Subscription Receipts issued pursuant to the Offering will be automatically exercised into 20,014,000 common shares of the Corporation (each, a "Common Share") and 10,007,000 common share purchase warrants of the Corporation (each, a "Warrant") for gross proceeds of C$10.007 million. Each Warrant entitles the holder thereof to purchase one Common Share at an exercise price of $0.90 for a period of 12 months from the date of issuance.

It is expected that the Corporation will use a portion of the escrowed proceeds to fund the cash consideration (the "Cash Consideration") payable to the vendors in connection with the Transaction. In connection with the closing of the Transaction, the Corporation also issued 6,470,588 Common Shares at a deemed price of $0.425 per Share to the vendors (together with the Cash Consideration, the "Consideration").

In connection with the Private Placement, the Corporation paid to eligible arm’s length parties (each a “Finder”): (i) an aggregate cash fee $383,695; and (ii) 1,019,921 Finders warrants (each a “Finder Warrant”). Each Finder Warrant will be exercisable into one additional common share at an exercise price of $0.90 per share for a period of 12 months from the closing of the Transaction.

All securities issued pursuant to the Transaction and the Finder Warrants are subject to a statutory hold period of four months and one day, expiring on June 19, 2022.

Certain insiders of the Corporation subscribed for 1,186,000 Subscription Receipts under the Offering and such transaction is considered to be a “related party transaction” as defined under Multilateral Instrument 61-101 (“MI 61-101”). The transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of any securities issued to or the consideration paid exceeded 25% of the Corporation’s market capitalization.

Grant of Options

Lastly the Corporation’s board of directors has approved the grant of stock options (the “Options”) exercisable for a total of 6,029,412 common shares (“Common Shares”) to its directors, officers, employees and consultants. All Options were granted pursuant to the Corporation’s stock option plan and are subject to the terms of the applicable grant agreements and the requirements of the TSX Venture Exchange.

The Options were granted at an exercise price of $0.50. 3,529,412 Options shall expire on February 18, 2024, and 2,500,000 Options shall expire on February 18, 2027.

Share issuance to Agora
Further to its news release of April 21, 2021, on January 12, 2022, Intema issued an aggregate of 59,154 common shares of the Corporation at a deemed price of $0.355 per share to Agora Internet Relations Corp. in consideration of services rendered.

About LOOT.BET
LOOT.BET is one of the global leaders in esports betting, with a focus on live betting and online gaming and building an exceptional product for its 450,000+ registered users. Supported by a professional operational and software development team of over 50 employees, LOOT.BET is world-renowned not only as an established and reliable esports betting platform but also as a supporter of the esports industry. It is a regular sponsor of notable professional tournaments and teams and a partner of leading esports operators, studios and bright esports talents and influencers. It is also a proud supporter of the anti-corruption esports Integrity Commission, helping the organization combat match-fixing and betting fraud, thereby contributing to the development and maturing of both the esports and the esports betting industries. For more information, please visit LOOT.BET.

About Intema
Intema Solutions Inc. is the emerging world leader in the esports and iGaming industry. Our mission is to bring the excitement of esports betting to the entire world through fully licensed, secure online platforms. Our ecosystem consists of subsidiaries in esports, iGaming, product branding, digital advertising and marketing campaign design that are all complementary drivers of our future revenue growth. For more information, please visit our corporate website at intema.ca.

Contact
Laurent Benezra
President and CEO
514-861-1881
info@intema.ca

Forward-Looking Statements
This press release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements” within the meaning of applicable Canadian securities laws. All statements, other than statements of historical facts, included in this press release, including, without limitation, those regarding the Private Placement; the expected development of the Corporation’s business and projects; execution of the Corporation’s vision and growth strategy; sources and availability of financing for the Corporation’s projects; and future liquidity, working capital, and capital requirements, are forward-looking statements. Although the forward-looking statements in this press release are based upon what management of the Corporation believes are reasonable assumptions, they are inherently subject to significant business, economic and competitive uncertainties, and contingencies, and there can be no assurance that they will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-Looking statements can generally be identified by the use of forward-looking words such as “may”, “should”, “will”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this press release relate to, among other things, statements relating to the terms of the Private Placement and the terms of the Proposed Transaction; Intema’s future outlook and anticipated events or results; and the completion of the Private Placement and the Proposed Transaction. Actual future results may differ materially. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause future results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. The Corporation’s statements expressed or implied by these forward-looking statements are subject to a number of risks, uncertainties, and conditions, many of which are outside of the Corporation’s control, and undue reliance should not be placed on such statements. Forward-looking statements are qualified in their entirety by the inherent risks and uncertainties surrounding the Private Placement and the Proposed Transaction, including: that the Corporation’s assumptions in making forward-looking statements may prove to be incorrect; general adverse market conditions and competition; the inability to finance operations and/or obtain any future strategic investment necessary to implement new technologies; the inability to build a sustainable, conscientious company with a stronger presence online through new products in esports and gaming; the inability to obtain, or maintain, gaming license(s); and that market conditions related to the COVID-19 pandemic may negatively affect the outcome of the business or operations of the Corporation, including its results and financial condition. Except as required by securities law, the Corporation does not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. The Corporation undertakes no obligation to update forward-looking statements except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

$VXIT VirExit Technologies Announces Growth Phase in Shareholder Update
Press Release | 02/22/2022
Company has hired a significant sales force, registered for a new SEC investment offering, and introduced a new trademarked product.

RICHLAND, WA / ACCESSWIRE / February 22, 2022 / VirExit Technologies, Inc (OTC PINK:VXIT) is pleased to announce it has added significant head count to its already-robust team. The company has added over a dozen direct salespeople that are currently working within specific targeted markets, including everything from aviation to education. The company has also made it clear that there will be more consistent communication with stakeholders and expects its' growth to continue.

The company has several open positions, including a Director of Sales. It is currently interviewing for that position and others, and requests that candidates email a resume to jim@virexit.com. In tandem with this, the company has submitted the paperwork for a RegA Tier 1 offering for $5million on January 24, 2022. The SEC has completed their response. We will be qualified to raise these funds as soon as the first U.S. state accepts our pending request.

"We have been doing a deep dive to gain a better understanding of where we sit on the value chain and stakeholder's expectations. We are also preparing for our growth and to increase market share. Through this discovery process, we recognized and confirmed that there is a lot more we could and will do," said James C. Katzaroff, CEO, VirExit Technologies, Inc.

The company has completed significant research and, according to Web Barth, COO, VirExit Airline Division, "even with some mask mandates being lifted, the demand for a more comfortable as well as a safer mask is at its highest point right now, as many are also preparing for the next potential surge."

VirExit's research has uncovered empirical evidence that there is no more effective mask material, than LivingGuard, available on the market today. "Our associates, FineHH, have afforded us the unique opportunity to market this as well as several other products. Branded VirExitBreatheEasy™ mask, we believe this customized mask to be the most comfortable, breathable, all-day mask. There is no other customized mask like the VirExitBreathEasy mask in the world," noted Katzaroff.

FineHH has utilized laboratory results for its fabric from Product Safety Labs, Freie Universitaet, Berlin, the University of Arizona, and the government of Singapore. The fabric is also endorsed by The Medical Wellness Association. The VirExitBreatheEasy mask, utilizing the same fabric in a custom design, offers almost complete protection-a 99.5% kill rate on contact from Covid, Delta, Omicron, as well as influenza, and others.

"I wish to recognize and thank the extraordinary efforts of our CFO Bruce Jolliff, as well as Web Barth, Patrick Netter, and David Croom. As initial ‘dream-team collaborators' they are plank-holders and are highly-valued within the organization," said Katzaroff. "I anticipate 2022 to be a breakthrough year with our collective efforts. We have recently added entrepreneur James Chism and expect to add several senior-level professional leaders that are well-versed in commercial transactions as well as investment banking. We are laser-focused and are passionate to increase stakeholder value in the immediate future.

About VirExit Technologies, Inc.

VirExit Technologies, Inc. (VXIT) is a diversified company focused on innovative, effective, ethical, and safe products within the health, safety, and wellness verticals. In 2020, the company purchased SaferPlace Technologies, LLC, whose purpose is to create a primary sales and marketing platform as a vertical online marketplace. This acquisition seeks to provide a single source for buyers and sellers of protective products and services which resonate with the VirExit Technologies mission statement: making the world a healthier and safer place with innovative, ethical and effective technologies.

For investor relations information please contact investorrelations@virexit.com.

SOURCE: VirExit Technologies, Inc (OTC PINK:VXIT)

$VXIT VirExit Technologies Announces Growth Phase in Shareholder Update
Press Release | 02/22/2022
Company has hired a significant sales force, registered for a new SEC investment offering, and introduced a new trademarked product.

RICHLAND, WA / ACCESSWIRE / February 22, 2022 / VirExit Technologies, Inc (OTC PINK:VXIT) is pleased to announce it has added significant head count to its already-robust team. The company has added over a dozen direct salespeople that are currently working within specific targeted markets, including everything from aviation to education. The company has also made it clear that there will be more consistent communication with stakeholders and expects its' growth to continue.

The company has several open positions, including a Director of Sales. It is currently interviewing for that position and others, and requests that candidates email a resume to jim@virexit.com. In tandem with this, the company has submitted the paperwork for a RegA Tier 1 offering for $5million on January 24, 2022. The SEC has completed their response. We will be qualified to raise these funds as soon as the first U.S. state accepts our pending request.

"We have been doing a deep dive to gain a better understanding of where we sit on the value chain and stakeholder's expectations. We are also preparing for our growth and to increase market share. Through this discovery process, we recognized and confirmed that there is a lot more we could and will do," said James C. Katzaroff, CEO, VirExit Technologies, Inc.

The company has completed significant research and, according to Web Barth, COO, VirExit Airline Division, "even with some mask mandates being lifted, the demand for a more comfortable as well as a safer mask is at its highest point right now, as many are also preparing for the next potential surge."

VirExit's research has uncovered empirical evidence that there is no more effective mask material, than LivingGuard, available on the market today. "Our associates, FineHH, have afforded us the unique opportunity to market this as well as several other products. Branded VirExitBreatheEasy™ mask, we believe this customized mask to be the most comfortable, breathable, all-day mask. There is no other customized mask like the VirExitBreathEasy mask in the world," noted Katzaroff.

FineHH has utilized laboratory results for its fabric from Product Safety Labs, Freie Universitaet, Berlin, the University of Arizona, and the government of Singapore. The fabric is also endorsed by The Medical Wellness Association. The VirExitBreatheEasy mask, utilizing the same fabric in a custom design, offers almost complete protection-a 99.5% kill rate on contact from Covid, Delta, Omicron, as well as influenza, and others.

"I wish to recognize and thank the extraordinary efforts of our CFO Bruce Jolliff, as well as Web Barth, Patrick Netter, and David Croom. As initial ‘dream-team collaborators' they are plank-holders and are highly-valued within the organization," said Katzaroff. "I anticipate 2022 to be a breakthrough year with our collective efforts. We have recently added entrepreneur James Chism and expect to add several senior-level professional leaders that are well-versed in commercial transactions as well as investment banking. We are laser-focused and are passionate to increase stakeholder value in the immediate future.

About VirExit Technologies, Inc.

VirExit Technologies, Inc. (VXIT) is a diversified company focused on innovative, effective, ethical, and safe products within the health, safety, and wellness verticals. In 2020, the company purchased SaferPlace Technologies, LLC, whose purpose is to create a primary sales and marketing platform as a vertical online marketplace. This acquisition seeks to provide a single source for buyers and sellers of protective products and services which resonate with the VirExit Technologies mission statement: making the world a healthier and safer place with innovative, ethical and effective technologies.

For investor relations information please contact investorrelations@virexit.com.

SOURCE: VirExit Technologies, Inc (OTC PINK:VXIT)

$SIRC Solar Integrated Roofing Corp. Secures $45 Million Co-Development Agreement for Georgia School Solar Projects
Press Release | 02/22/2022
SIRC Subsidiary USA Solar Networks to Manage Construction, Capital Structuring and Materials Procurement Spanning 17 High School Solar Installations

EL CAJON, CA / ACCESSWIRE / February 22, 2022 / Solar Integrated Roofing Corp. (OTC PINK:SIRC), an integrated, single-source solar power, roofing systems installation and EV charging company, has secured a co-development agreement with Lux Power for the installation of 17 solar projects at private high schools across the state of Georgia.

The projects in aggregate total 17 Megawatts of solar capacity with a contract value exceeding $45 million. SIRC subsidiary USA Solar Networks will manage construction, the structuring of capital solutions and facilitate all materials procurement for these projects.

Pablo Diaz, President of Solar Integrated Roofing Corp., said: "This contract represents a significant project win not only for our company and valued shareholders - but for the schools themselves. As the son of a former principal, I know how many educational institutions often face budget shortfalls. This project is expected to save hundreds of thousands of dollars per year for each school, allowing necessary funds to better contribute to an improved educational experience. In addition, we will partner with the schools to enable their solar installations to serve as an invaluable educational tool, promoting the importance of sustainability and green energy."

David Massey, CEO of Solar Integrated Roofing Corp., concluded: "This is yet another example of how our projects make a real world impact for the better - a firm testament to the impact we have on our local communities. We look forward to working with the Lux Power team to make these projects a reality, providing value for all stakeholders."

About Solar Integrated Roofing Corp.

Solar Integrated Roofing Corp. (OTC:SIRC), is an integrated, single-source solar power, roofing systems installation and EV charging company specializing in commercial and residential properties throughout the United States. The Company serves communities by delivering the best experience through constant innovation & legacy-focused leadership. The Company's broad array of solutions include sales and installation of solar energy systems, battery backup and electric vehicle (EV) charging stations to roofing, HVAC and related electrical contracting work. For more information, please visit the Company's website at www.solarintegratedroofing.com.

Forward-Looking Statements

Any statements made in this press release which are not historical facts contain certain forward-looking statements; as such term is defined in the Private Security Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update the information contained in any forward-looking statement. This press release shall not be deemed a general solicitation.

Investor Relations Contact:
Lucas A. Zimmerman
Director
MZ North America
Main: 949-259-4987
SIRC@mzgroup.us
www.mzgroup.us

$SIRC Solar Integrated Roofing Corp. Secures $45 Million Co-Development Agreement for Georgia School Solar Projects
Press Release | 02/22/2022
SIRC Subsidiary USA Solar Networks to Manage Construction, Capital Structuring and Materials Procurement Spanning 17 High School Solar Installations

EL CAJON, CA / ACCESSWIRE / February 22, 2022 / Solar Integrated Roofing Corp. (OTC PINK:SIRC), an integrated, single-source solar power, roofing systems installation and EV charging company, has secured a co-development agreement with Lux Power for the installation of 17 solar projects at private high schools across the state of Georgia.

The projects in aggregate total 17 Megawatts of solar capacity with a contract value exceeding $45 million. SIRC subsidiary USA Solar Networks will manage construction, the structuring of capital solutions and facilitate all materials procurement for these projects.

Pablo Diaz, President of Solar Integrated Roofing Corp., said: "This contract represents a significant project win not only for our company and valued shareholders - but for the schools themselves. As the son of a former principal, I know how many educational institutions often face budget shortfalls. This project is expected to save hundreds of thousands of dollars per year for each school, allowing necessary funds to better contribute to an improved educational experience. In addition, we will partner with the schools to enable their solar installations to serve as an invaluable educational tool, promoting the importance of sustainability and green energy."

David Massey, CEO of Solar Integrated Roofing Corp., concluded: "This is yet another example of how our projects make a real world impact for the better - a firm testament to the impact we have on our local communities. We look forward to working with the Lux Power team to make these projects a reality, providing value for all stakeholders."

About Solar Integrated Roofing Corp.

Solar Integrated Roofing Corp. (OTC:SIRC), is an integrated, single-source solar power, roofing systems installation and EV charging company specializing in commercial and residential properties throughout the United States. The Company serves communities by delivering the best experience through constant innovation & legacy-focused leadership. The Company's broad array of solutions include sales and installation of solar energy systems, battery backup and electric vehicle (EV) charging stations to roofing, HVAC and related electrical contracting work. For more information, please visit the Company's website at www.solarintegratedroofing.com.

Forward-Looking Statements

Any statements made in this press release which are not historical facts contain certain forward-looking statements; as such term is defined in the Private Security Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update the information contained in any forward-looking statement. This press release shall not be deemed a general solicitation.

Investor Relations Contact:
Lucas A. Zimmerman
Director
MZ North America
Main: 949-259-4987
SIRC@mzgroup.us
www.mzgroup.us

$GGII Green Globe International and Subsidiaries to Exhibit at ASD Market Week in Las Vegas, February 27 - March 2, in Booth #W10619
Press Release | 02/18/2022
San Diego, California--(Newsfile Corp. - February 18, 2022) - Green Globe International Inc. (OTC Pink: GGII) ("GGII") plans to exhibit at ASD Market Week in Las Vegas on February 27 - March 2 in booth W10619. Hempacco Co, Inc., a majority-owned subsidiary of GGII, will occupy half of the booth where it will feature The Real Stuff Hemp Smokables, Rick Ross' Hemp Hop Smokables and Wraps, and Cheech & Chong Smokables and Wraps. Green Star Labs, Inc., a fifty-percent owned entity of GGII, will occupy the other half of the booth and introduce its new Real Stuff product line of CBD, nutritional supplement, and beauty care products. The goal is to land master distributors for GGII's entire product lines.

Details of the ASD Market Week 2022:

Show Dates: February 27 - March 2, 2022

Location: Las Vegas Convention Center, North and West Halls
GGII's Booth Number: W10619
Show Times: 9 am - 6 pm PST
Sample Hempacco's latest Hemp CBD Real Stuff Smokables, Hemp Hop Smokables and Wraps, and Cheech & Chong Smokables and Wraps.
Try out Green Star Labs' new Real Stuff CBD, nutraceutical, and beauty care product line.
See the Rick Ross and Cheech & Chong kiosk machines with advertising screens.
GGII will hold private meetings with interested distributors, retailers, wholesalers, and buyers after the show at a daily hosted happy hour at their Westgate Hotel Suite. Distributors can contact the team at (775) 473-1201 for badges and RSVP for evening meetings on February 27, 28, and March 1. ASD Market Week is a huge show that brings the widest selection of wholesale consumer merchandise across two buildings.

"We are excited to be exhibiting for the first time at the ASD Show this year," commented Sandro Piancone, CEO of GGII. "We are eager to launch our Real Stuff, Hemp Hop, and Cheech and Chong Smokables to the buyers at ASD. Our brands come with marketing support, merchandising, and salespeople to help open new accounts," continued Sandro Piancone.

"I've been attending the ASD show for 20 years, and it's my favorite show in the world because it is a buying show. People come looking for a product and can buy a master case, pallet, or a truckload," said Jorge Olson, GGII's CMO. "I'm thrilled to be back now with GGII, Hempacco, and Green Star Labs promoting our smokables and new lines of CBD, beauty, and nutraceutical products," concluded Jorge Olson.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7978/114133_GGII%20at%20ASD%20Show%20LV%202022_550.jpg

GGII at ASD Show Las Vegas 2022

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7978/114133_GGII%20at%20ASD%20Show%20LV%202022.jpg

Forward-Looking and Cautionary Statements?

This news release may include forward-looking statements including opinions, assumptions, estimates, the Company's assessment of future plans and operations, including but not limited to information concerning a potential combination with Hempacco and the timing thereof. When used in this document, the words "will," "anticipate," "believe," "estimate," "expect," "intent," "may," "project," "should," and similar expressions are intended to be among the statements that identify forward-looking statements. The forward-looking statements are founded based on expectations and assumptions made by the Company. Forward-looking statements are subject to a wide range of risks and uncertainties. Although the Company believes that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will be realized. Any number of important factors could cause actual results to differ materially from those in the forward-looking statements including, but not limited to regulatory and third party approvals not being obtained in the manner or timing anticipated; the ability to implement corporate strategies; the state of domestic capital markets; the ability to obtain financing; changes in general market conditions; industry conditions and events; and other factors more fully described from time to time in the reports and filings made by the Company with OTC Markets Group, Inc. or the securities regulatory authorities. Except as required by applicable laws, the Company does not undertake any obligation to publicly update or revise forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of relevant securities laws and considered forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended.?

# # #?

About Green Globe International, Inc. (GGII):
Green Globe and its subsidiaries develop, manufacture, market, and sell consumer goods, including herb and hemp smokables rolling paper. It trades on the OTC under the ticker GGII.?

Green Globe and its subsidiaries current projects include:

Herb and Cannabinoid Cigarettes, including CBD Cigarettes?
Manufacturing hemp rolling papers called hemp blunts
CBD, nutritional supplements, and beauty care products
Online sales of CBD products?
Joint Ventures with large distributors and celebrities like Rick Ross and Cheech & Chong?
The Real Stuff brand of hemp smokables?
Add Your Name to the?GGII Investor Email List?
To be added to GGII's?investor email list and be kept apprised of all upcoming IR activities, please subscribe using this link:?https://newsroom.newsfilecorp.com/lists/8020/490

Company Contact:? ?
Sandro?Piancone, CEO,?or Investor Relations?IR@hempaccopackaging.com

Investor Contact:
Dave Gentry, CEO
RedChip Companies
GGII@redchip.com
1-800-733-2447

$FFWC FFW Corporation Announces Quarterly Cash Dividend, Share Repurchase
Press Release | 02/18/2022
WABASH, Ind., Feb. 18, 2022 (GLOBE NEWSWIRE) -- FFW Corporation (OTC PINK: FFWC) (02/17/22 Close: $47.37), parent corporation of Crossroads Bank, has approved a quarterly cash dividend of $0.26 per share of common stock. The dividend is payable March 31, 2022 to shareholders of record on March 17, 2022.

The book value of FFW Corporation stock was $47.00 per share as of January 31, 2022. The last reported trade of stock at the close of business on February 17, 2022 was $47.37 per share and the number of outstanding shares was 1,143,377 as of the same date. On January 31, 2022, the corporation had assets of $523.9 million and shareholders' equity of $53.7 million. The Board of FFW Corporation and Crossroads Bank will continue to evaluate the payment of a dividend on a quarterly basis.

The corporation has an active walk-in share repurchase program. Share repurchases may be facilitated at the corporate office located at 1205 N. Cass St., Wabash IN 46992. For more information regarding the share repurchase program, please contact Kirsten Pendarvis, Treasurer, at (260) 563-3185. The corporation may suspend or discontinue repurchases at any time.

Crossroads Bank is a wholly owned subsidiary of FFW Corporation, providing an extensive array of banking services and a wide range of investments and securities products through its main office in Wabash and six Indiana banking centers located in Columbia City, North Manchester, Peru, South Whitley, Syracuse and Warsaw. The Bank also provides leasing services at each of its banking centers. Insurance products are offered through an affiliated company, Insurance 1 Services, Inc. The Corporation’s stock is traded on the OTC Markets under the symbol “FFWC.” Our website address is www.crossroadsbanking.com. Crossroads Bank, Member FDIC.

FOR MORE INFORMATION
Kirsten Pendarvis
Treasurer
(260) 563-3185

$WPUR ALYI Reports On Expanding EV Ecosystem Revenue Streams
Press Release | 02/18/2022
Dallas, Texas, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Alternet Systems, Inc. (OTC Pink: ALYI) today publish a progress report update on the company’s 2022 strategic outlook to reach $10 million in organic revenue with the potential to reach a $50 million stretch revenue goal. The update comes in the form of a shareholder letter from ALYI CEO Randell Torno. The letter is included in its entirety below:

Dear Shareholders:

ALYI has entered into 2022 at a very exciting juncture in the development of our EV Ecosystem business. That juncture is the transition from concept development to revenue traction.

ALYI is now generating revenue from the sale of electric motorcycles and three-wheeled electric Bahas. Our EV sales are only one component of our EV Ecosystem where we expect to generate revenue, and we are now on the verge of seeing additional revenue streams from other EV Ecosystem components begin to make the transition from concept to revenue traction.

One might think the ALYI share price would react more positively to the transition from concept to revenue. However, ALYI’s transition has coincided with a market weighted with more uncertainty than confidence. Inciting a positive reaction for any positive progress is an uphill battel for any company at this moment.

Nonetheless, ALYI is proceeding with our transition even though the progress we make today may not be immediately reflected in our share price while market uncertainty prevails. I am confident optimism will return to the market and the progress ALYI makes now will later be recognized.

I encourage you to review the ALYI 2022 strategic outlook presentation that explains how the various components of the company’s EV Ecosystem fit together to drive revenue and shareholder value.

The 2022 strategic outlook plans for ALYI to reach $10 million in organic revenue with the potential for us to reach a $50 million stretch revenue goal.

We expect the $10 million in organic revenue to come from our growing EV sales. We have established a comprehensive platform that we believe can soundly advance the growth of our EV sales. ALYI has established distribution and shared ride management partnerships in Africa that facilitate the entire lifecycle of our electric motorcycles and Bajas once they are produced. Our platform in Africa is licensed to import and has the backing to finance motorcycles for shared ride drivers through a lease to own contract.

Our EV sales opportunity could be greater than $10 million, and we certainly won’t rule out the potential to increase our 2022 EV sales target. In the meantime, the additional revenue that would take us to our stretch revenue goal targeting $50 million is anticipated from other components of our EV Ecosystem.

Our partnership with Priority Aviation, Inc. (OTC Pink: PJET), a company that is no longer in the aviation business having transitioned into a business serving university students, could soon begin generating additional revenue for ALYI. ALYI is providing electric motorcycles to PJET for a pilot university student campus transportation program that could expand from a pilot into a full-fledged program. PJET expects to start demonstrating vehicles on campuses in Texas before the end of the first quarter and taking orders.

ALYI has also partnered with WaterPure International, Inc. (OTC Pink: WPUR), a water utility management company that has expanded into electric utility management focusing on innovative sustainability technology projects in Africa that can be scaled globally. ALYI is working on multiple projects with WPUR. Our off grid electric vehicle charging project has the potential to start generating revenue later this year for both ALYI and WPUR.

From our current vantage point, the most substantial stretch revenue contribution would come from ALYI’s direct investment the shared mobility market. The shared mobility market reached $420 billion in 2020 and is expected to reach $770 billion by 2030. ALYI’s investment is both tactical and strategic. The investment could tactically produce a significant monetary return on investment and strategically, it could substantially expand ALYI’s EV sales.

ALYI has made a strategic monetary investment in a car sharing technology company called Zoomcar Inc.

Early Zoomcar investors include Sequoia Capital, former US Treasury Secretary Larry Summers, Mahindra & Mahindra Ltd. and Ford Smart Mobility LLC, a unit of Ford Motor Co.

We are optimistic about the tactical and strategic ROI potential of ALYI’s investment, and that optimism is growing in reaction to recent news on Zoomcar’s progress:

“Zoomcar, an India-headquartered self-drive car rental platform operator, plans to get listed in the US in the first half of 2022 with an expected valuation of over USD 1bn” said co-founder and CEO Greg Moran.

"The company is still assessing both traditional initial public offering (IPO) and SPAC routes and will finalize the advisory team in the coming months", Moran said.

ALYI has just executed a new agreement that advances our brand name electric auto racing event initiative in Kenya around which we intend to build a major, annual global EV symposium to advance EV technology worldwide. I look forward to sharing more details on our event progress in a future update.

With a population approaching 8 billion people, and with less that 2 billion of the population living within a developed economy, the world has boundless opportunity for economic growth. The current market uncertainty will eventually be overcome by that massive economic growth opportunity. Here at ALYI, we never lose sight of that massive economic growth opportunity.

Sincerely,
Randell Torno
CEO ALYI

For more information and to stay up to date on ALYI's overall latest developments, please visit www.alternetsystemsinc.com.

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Alternet Systems, Inc.
Randell Torno
info@lithiumip.com
+1-800-713-0297

$WPUR ALYI Reports On Expanding EV Ecosystem Revenue Streams
Press Release | 02/18/2022
Dallas, Texas, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Alternet Systems, Inc. (OTC Pink: ALYI) today publish a progress report update on the company’s 2022 strategic outlook to reach $10 million in organic revenue with the potential to reach a $50 million stretch revenue goal. The update comes in the form of a shareholder letter from ALYI CEO Randell Torno. The letter is included in its entirety below:

Dear Shareholders:

ALYI has entered into 2022 at a very exciting juncture in the development of our EV Ecosystem business. That juncture is the transition from concept development to revenue traction.

ALYI is now generating revenue from the sale of electric motorcycles and three-wheeled electric Bahas. Our EV sales are only one component of our EV Ecosystem where we expect to generate revenue, and we are now on the verge of seeing additional revenue streams from other EV Ecosystem components begin to make the transition from concept to revenue traction.

One might think the ALYI share price would react more positively to the transition from concept to revenue. However, ALYI’s transition has coincided with a market weighted with more uncertainty than confidence. Inciting a positive reaction for any positive progress is an uphill battel for any company at this moment.

Nonetheless, ALYI is proceeding with our transition even though the progress we make today may not be immediately reflected in our share price while market uncertainty prevails. I am confident optimism will return to the market and the progress ALYI makes now will later be recognized.

I encourage you to review the ALYI 2022 strategic outlook presentation that explains how the various components of the company’s EV Ecosystem fit together to drive revenue and shareholder value.

The 2022 strategic outlook plans for ALYI to reach $10 million in organic revenue with the potential for us to reach a $50 million stretch revenue goal.

We expect the $10 million in organic revenue to come from our growing EV sales. We have established a comprehensive platform that we believe can soundly advance the growth of our EV sales. ALYI has established distribution and shared ride management partnerships in Africa that facilitate the entire lifecycle of our electric motorcycles and Bajas once they are produced. Our platform in Africa is licensed to import and has the backing to finance motorcycles for shared ride drivers through a lease to own contract.

Our EV sales opportunity could be greater than $10 million, and we certainly won’t rule out the potential to increase our 2022 EV sales target. In the meantime, the additional revenue that would take us to our stretch revenue goal targeting $50 million is anticipated from other components of our EV Ecosystem.

Our partnership with Priority Aviation, Inc. (OTC Pink: PJET), a company that is no longer in the aviation business having transitioned into a business serving university students, could soon begin generating additional revenue for ALYI. ALYI is providing electric motorcycles to PJET for a pilot university student campus transportation program that could expand from a pilot into a full-fledged program. PJET expects to start demonstrating vehicles on campuses in Texas before the end of the first quarter and taking orders.

ALYI has also partnered with WaterPure International, Inc. (OTC Pink: WPUR), a water utility management company that has expanded into electric utility management focusing on innovative sustainability technology projects in Africa that can be scaled globally. ALYI is working on multiple projects with WPUR. Our off grid electric vehicle charging project has the potential to start generating revenue later this year for both ALYI and WPUR.

From our current vantage point, the most substantial stretch revenue contribution would come from ALYI’s direct investment the shared mobility market. The shared mobility market reached $420 billion in 2020 and is expected to reach $770 billion by 2030. ALYI’s investment is both tactical and strategic. The investment could tactically produce a significant monetary return on investment and strategically, it could substantially expand ALYI’s EV sales.

ALYI has made a strategic monetary investment in a car sharing technology company called Zoomcar Inc.

Early Zoomcar investors include Sequoia Capital, former US Treasury Secretary Larry Summers, Mahindra & Mahindra Ltd. and Ford Smart Mobility LLC, a unit of Ford Motor Co.

We are optimistic about the tactical and strategic ROI potential of ALYI’s investment, and that optimism is growing in reaction to recent news on Zoomcar’s progress:

“Zoomcar, an India-headquartered self-drive car rental platform operator, plans to get listed in the US in the first half of 2022 with an expected valuation of over USD 1bn” said co-founder and CEO Greg Moran.

"The company is still assessing both traditional initial public offering (IPO) and SPAC routes and will finalize the advisory team in the coming months", Moran said.

ALYI has just executed a new agreement that advances our brand name electric auto racing event initiative in Kenya around which we intend to build a major, annual global EV symposium to advance EV technology worldwide. I look forward to sharing more details on our event progress in a future update.

With a population approaching 8 billion people, and with less that 2 billion of the population living within a developed economy, the world has boundless opportunity for economic growth. The current market uncertainty will eventually be overcome by that massive economic growth opportunity. Here at ALYI, we never lose sight of that massive economic growth opportunity.

Sincerely,
Randell Torno
CEO ALYI

For more information and to stay up to date on ALYI's overall latest developments, please visit www.alternetsystemsinc.com.

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Alternet Systems, Inc.
Randell Torno
info@lithiumip.com
+1-800-713-0297

$RSHN Core One Labs’ Files Milestone Patent for Protection of its Recombinant Production System for Optimized Biosynthetic N-methyltryptamine (NMT)
Press Release | 02/21/2022
VANCOUVER, British Columbia, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that its wholly-owned subsidiary, Vocan Biotechnologies Inc. of Victoria, British Columbia, has filed a patent application with the United States Patent and Trademark Office (“USPTO”) for the production of biosynthetic N-methyltryptamine (NMT) (also known as monomethyl tryptamine (MMT)) through its optimized recombinant production system (the “System”). N-Methyltryptamine is a member of tryptamines and is an organic compound known to produce psychoactive effects when combined with a monoamine oxidase A inhibitor (MAOI).1

The patent entitled “Production of Psychedelic Compounds” protects Core One’s novel proprietary production system. The System, under the leadership of Dr. Jan Burian, Chief Scientist, and Dr. Robert EW Hancock, is designed to make bacteria act as a biological factory and produce bioidentical psychedelic analogs such as biosynthetic N-methyltryptamine (NMT).

The Company's unique production process can manufacture a more superior cGMP compliant API grade NMT (or other psychedelic products) than any chemically synthesized counterpart, since it retains the stereochemistry of the natural psychedelic analogs found in hallucinogenic mushrooms. Natural psilocybin and psychedelic-related molecules are known to have a more positive effect than those chemically synthesized; however, analog compounds can potentially be more effective and safer than natural compounds.

A final patent approval would propel Core One past industry rivals since their game-changing production process enables mass-production of synthetic psilocybin and other psychedelic compounds or analogs more rapidly, while also reducing the production cost and market price drastically. It also maintains the quality and efficacy that are usually present in organically produced psychedelics.

“Filing this patent is an important milestone for the company since it allows us to protect our intellectual property against potential competitors. The patent provides a broad array of strategies useful for making psychedelic compounds enabling Core One to diversify its product portfolio,” stated Dr. Bob Hancock, CEO of Vocan Biotechnologies.

ABOUT CORE ONE LABS INC.
Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

CORE ONE LABS INC.
Joel Shacker
Chief Executive Officer

FOR FURTHER INFORMATION:
Email: info@core1labs.com
Telephone: 1-866-347-5058

FOLLOW US:
Website: https://core1labs.com/
Twitter: https://twitter.com/Coreonelabs
Facebook: https://www.facebook.com/Core-One-Labs-Inc-100969251278277/
LinkedIn: https://www.linkedin.com/company/core-one-labs
Instagram: https://www.instagram.com/coreonelabsinc/

CAUTIONARY DISCLAIMER STATEMENT
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

$CLABF Core One Labs’ Files Milestone Patent for Protection of its Recombinant Production System for Optimized Biosynthetic N-methyltryptamine (NMT)
Press Release | 02/21/2022
VANCOUVER, British Columbia, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that its wholly-owned subsidiary, Vocan Biotechnologies Inc. of Victoria, British Columbia, has filed a patent application with the United States Patent and Trademark Office (“USPTO”) for the production of biosynthetic N-methyltryptamine (NMT) (also known as monomethyl tryptamine (MMT)) through its optimized recombinant production system (the “System”). N-Methyltryptamine is a member of tryptamines and is an organic compound known to produce psychoactive effects when combined with a monoamine oxidase A inhibitor (MAOI).1

The patent entitled “Production of Psychedelic Compounds” protects Core One’s novel proprietary production system. The System, under the leadership of Dr. Jan Burian, Chief Scientist, and Dr. Robert EW Hancock, is designed to make bacteria act as a biological factory and produce bioidentical psychedelic analogs such as biosynthetic N-methyltryptamine (NMT).

The Company's unique production process can manufacture a more superior cGMP compliant API grade NMT (or other psychedelic products) than any chemically synthesized counterpart, since it retains the stereochemistry of the natural psychedelic analogs found in hallucinogenic mushrooms. Natural psilocybin and psychedelic-related molecules are known to have a more positive effect than those chemically synthesized; however, analog compounds can potentially be more effective and safer than natural compounds.

A final patent approval would propel Core One past industry rivals since their game-changing production process enables mass-production of synthetic psilocybin and other psychedelic compounds or analogs more rapidly, while also reducing the production cost and market price drastically. It also maintains the quality and efficacy that are usually present in organically produced psychedelics.

“Filing this patent is an important milestone for the company since it allows us to protect our intellectual property against potential competitors. The patent provides a broad array of strategies useful for making psychedelic compounds enabling Core One to diversify its product portfolio,” stated Dr. Bob Hancock, CEO of Vocan Biotechnologies.

ABOUT CORE ONE LABS INC.
Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

CORE ONE LABS INC.
Joel Shacker
Chief Executive Officer

FOR FURTHER INFORMATION:
Email: info@core1labs.com
Telephone: 1-866-347-5058

FOLLOW US:
Website: https://core1labs.com/
Twitter: https://twitter.com/Coreonelabs
Facebook: https://www.facebook.com/Core-One-Labs-Inc-100969251278277/
LinkedIn: https://www.linkedin.com/company/core-one-labs
Instagram: https://www.instagram.com/coreonelabsinc/

CAUTIONARY DISCLAIMER STATEMENT
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.

$CLABF Core One Labs’ Files Milestone Patent for Protection of its Recombinant Production System for Optimized Biosynthetic N-methyltryptamine (NMT)
Press Release | 02/21/2022
VANCOUVER, British Columbia, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that its wholly-owned subsidiary, Vocan Biotechnologies Inc. of Victoria, British Columbia, has filed a patent application with the United States Patent and Trademark Office (“USPTO”) for the production of biosynthetic N-methyltryptamine (NMT) (also known as monomethyl tryptamine (MMT)) through its optimized recombinant production system (the “System”). N-Methyltryptamine is a member of tryptamines and is an organic compound known to produce psychoactive effects when combined with a monoamine oxidase A inhibitor (MAOI).1

The patent entitled “Production of Psychedelic Compounds” protects Core One’s novel proprietary production system. The System, under the leadership of Dr. Jan Burian, Chief Scientist, and Dr. Robert EW Hancock, is designed to make bacteria act as a biological factory and produce bioidentical psychedelic analogs such as biosynthetic N-methyltryptamine (NMT).

The Company's unique production process can manufacture a more superior cGMP compliant API grade NMT (or other psychedelic products) than any chemically synthesized counterpart, since it retains the stereochemistry of the natural psychedelic analogs found in hallucinogenic mushrooms. Natural psilocybin and psychedelic-related molecules are known to have a more positive effect than those chemically synthesized; however, analog compounds can potentially be more effective and safer than natural compounds.

A final patent approval would propel Core One past industry rivals since their game-changing production process enables mass-production of synthetic psilocybin and other psychedelic compounds or analogs more rapidly, while also reducing the production cost and market price drastically. It also maintains the quality and efficacy that are usually present in organically produced psychedelics.

“Filing this patent is an important milestone for the company since it allows us to protect our intellectual property against potential competitors. The patent provides a broad array of strategies useful for making psychedelic compounds enabling Core One to diversify its product portfolio,” stated Dr. Bob Hancock, CEO of Vocan Biotechnologies.

ABOUT CORE ONE LABS INC.
Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

CORE ONE LABS INC.
Joel Shacker
Chief Executive Officer

FOR FURTHER INFORMATION:
Email: info@core1labs.com
Telephone: 1-866-347-5058

FOLLOW US:
Website: https://core1labs.com/
Twitter: https://twitter.com/Coreonelabs
Facebook: https://www.facebook.com/Core-One-Labs-Inc-100969251278277/
LinkedIn: https://www.linkedin.com/company/core-one-labs
Instagram: https://www.instagram.com/coreonelabsinc/

CAUTIONARY DISCLAIMER STATEMENT
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.